etoposide has been researched along with Lymphoma, Non-Hodgkin in 799 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (5.88) | 18.7374 |
| 1990's | 383 (47.93) | 18.2507 |
| 2000's | 248 (31.04) | 29.6817 |
| 2010's | 92 (11.51) | 24.3611 |
| 2020's | 29 (3.63) | 2.80 |
| Authors | Studies |
|---|---|
| de Lima, VCC; Filho, JS; Germano, JN; Matias Vieira, GM; Moura, FL; Sapelli, J | 1 |
| Grommes, C; Modelevsky, L; Reiss, SN; Yerram, P | 1 |
| Ashkenazi, M; Avni, B; Grisariu, S; Lebel, E; Stepensky, P; Vainstein, V; Zimran, E | 1 |
| Dong, T; Jing, F; Song, W; Wang, L; Wang, Y; Xiao, S; Xue, H | 1 |
| Akashi, K; Egashira, N; Hosohata, K; Ieiri, I; Ishida, S; Kato, K; Kawashiri, T; Miyamoto, T; Morikawa, H; Murata, S; Nakamura, T; Suetsugu, K; Tsuji, T; Uchida, M; Watanabe, H; Yonemitsu, H | 1 |
| Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM | 1 |
| Do, YR; Kang, HJ; Kim, HG; Kim, KH; Kim, WS; Kong, JH; Kwak, JY; Lee, JH; Lee, M; Mun, YC; Oh, SY; Park, MR; Park, SK; Park, Y; Shin, HJ; Won, JH; Yang, DH | 1 |
| Agreda-Vásquez, GP; Avendano, O; Barreyro, P; Cubero, D; Enrico, A; Fogliatto, L; Machnicki, G; Mela-Osorio, MJ; Ovilla, R; Pavlovsky, M; San Sebastián, JA; Trufelli, D; Villanova, P | 1 |
| Avni, B; Cohen, YI; Grisariu, S; Lebel, E; Shaulov, A; Stepensky, P; Zimran, E | 1 |
| Bai, B; Gao, Y; He, Y; Huang, C; Huang, H; Ping, L; Shi, L; Wang, X | 1 |
| Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P | 1 |
| Li, J; Ping, P; Sun, Y; Xu, Y; Yao, C; Yin, H | 1 |
| Chikasema, M; Chimzimu, F; Chiyoyola, S; Ellis, GK; Fedoriw, G; Gopal, S; Kaimila, B; Kampani, C; Kasonkanji, E; Mhango, W; Montgomery, ND; Mtangwanika, A; Mulenga, M; Nicholas, S; Nyasosela, R; Nyirenda, R; Painschab, MS; Randall, C; Tewete, B; Tomoka, T; Westmoreland, KD; Zuze, T | 1 |
| Cho, SH; Chung, JS; Jo, JC; Kim, DY; Shin, HJ | 1 |
| Aboulafia, D; Ambinder, RF; Cesarman, E; Chadburn, A; Henry, DH; Kaplan, LD; Lee, JY; Mitsuyasu, R; Noy, A; Ramos, JC; Ratner, L; Sparano, JA; Wachsman, W | 1 |
| Bartlett, NL | 1 |
| Bae, SH; Choi, Y; Jo, JC; Kim, IH; Kim, JS; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Yoon, SS | 1 |
| Fukunaga, A; Inano, S; Kitano, T; Okamoto, Y; Shibata, S; Tabata, S; Takiuchi, Y; Yamamoto, K | 1 |
| Bagot, M; Battistella, M; Bouaziz, JD; Brice, P; Dangien, A; de Masson, A; Lebbé, C; Moins-Teisserenc, H; Mourah, S; Peffault de Latour, R; Ram-Wolff, C; Roelens, M | 1 |
| Aboulafia, D; Ambinder, RF; Baiocchi, R; Capoferri, AA; Cesarman, E; Chadburn, A; Durand, CM; Kaplan, L; Lee, JY; Mitsuyasu, R; Moore, PC; Noy, A; Ramos, JC; Ratner, L; Reid, EG; Rubinstein, PG; Siegel, ER; Sparano, JA | 1 |
| Kang, KW; Kim, BS; Kim, JH; Kim, SJ; Lee, BH; Lee, SJ; Park, Y | 1 |
| Boyé, P; Floch, F; Fournel-Fleury, C; Serres, F; Tierny, D | 1 |
| Alpdogan, SO; Carabasi, M; Chapman, A; DiMeglio, M; Filicko-OHara, J; Flomenberg, N; Gaballa, S; Ghimire, S; Gong, J; Martinez-Outschoorn, U; Pan, J; Porcu, P; Pro, B; Ramirez, M; Rose, L; Wagner, JL; Weiss, M | 1 |
| Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L | 1 |
| Kheifetz, Y; Scholz, M | 1 |
| A Rouche, J; Abdayem, P; Danu, A; Dartigues, P; Desmaris, R; El Dakdouki, Y; Fermé, C; Ghez, D; Ibrahim, N; Lazarovici, J; Michot, JM; Ribrag, V; Rossignol, J; Willekens, C | 1 |
| Hojo, H; Ikeda, S; Koyama, D; Ohta, M; Sukegawa, M; Suzuki, M; Tsunoda, S | 1 |
| Grauer, D; Hoffmann, M; Konrardy, K; Roder, L | 1 |
| Birkmann, J; Blaudszun, AR; Bornhäuser, M; Ehninger, G; Fiedler, F; Fricke, S; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Kürzel, S; Schaefer-Eckart, K; Stahl, L | 1 |
| Ayed, AO; Chu, B; Farooq, U; Galanina, N; Link, BK; Malecek, MK; Maurer, M; Nabhan, C; Nowakowski, GS; Petrich, AM; Rozell, S; Trifilio, S | 1 |
| Jamil, MO; Khelfa, Y; Lebowicz, Y | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Dothard, A; Hurd, D; Isom, S; Kennedy, L; Lamar, ZS; Lesser, G; McClain, D; Robinson, M; Vaidya, R | 1 |
| Anwer, F; Guillén-Rodríguez, JM; Heard, K; Inclán, L; Mahadevan, D; Persky, DO; Puvvada, SD; Rivera, XI; Schatz, JH; Yan, J | 1 |
| Bruckner, T; Hensel, M; Ho, AD; Kriegsmann, K; Kriegsmann, M; Rieger, M; Schwarzbich, MA; Sitter, S; Witzens-Harig, M; Wuchter, P | 1 |
| Baran, A; Barr, PM; Casulo, C; David, RJ; Friedberg, JW; Loh, KP; Reagan, PM | 1 |
| Anagnostopoulos, A; Batsis, I; Bouziana, S; Constantinou, V; Gavriilaki, E; Mallouri, D; Marvaki, A; Sakellari, I; Sotiropoulos, D; Vardi, A | 1 |
| Cao, K; Cao, P; Huang, C; Li, X; Liu, L; Tian, R; Wang, L; Zhu, H | 1 |
| Izumitani, S; Kataoka, T; Matsuo, H; Murase, T; Nishigakiuchi, R; Saeki, Y; Sakurashita, H; Taogoshi, T | 1 |
| Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M | 1 |
| Cao, L; Fan, L; Li, JY; Liang, JH; Liao, H; Qian, J; Wang, L; Wu, JZ; Wu, W; Xia, Y; Xu, W; Zhu, HY | 1 |
| Aránguiz, N; Vega, J | 1 |
| Gao, TX; Huang, JJ; Jiang, WQ; Li, ZM; Sun, P; Sun, XQ; Wang, CQ; Wang, Y; Wu, K | 1 |
| Bahlis, NJ; Daly, A; Duan, Q; Duggan, P; Henning, JW; Shafey, M; Stewart, DA; Vijay, A | 1 |
| Czuczman, MS | 1 |
| Batchelor, TT | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 2 |
| Barta, SK; Boue, F; Dunleavy, K; Galicier, L; Garcia, O; Kaplan, LD; Lee, JY; Little, RF; Morgades, M; Mounier, N; Navarro, JT; Noy, A; Oriol, A; Ratner, L; Remick, SC; Ribera, JM; Sparano, JA; Spina, M; Tamari, R; Tirelli, U; Wang, D; Weiss, R; Wilson, WH; Wyen, C; Xue, X | 1 |
| Chung, JS; Kim, SK; Shin, HJ; Song, MK | 1 |
| Ahn, JS; Cheong, JW; Do, YR; Hyun, SY; Kim, JS; Kim, SJ; Lee, HS; Lee, JH; Lee, WS; Min, YH; Oh, SY; Ryoo, HM; Suh, C; Yang, DH; Yhim, HY | 1 |
| Levine, AM | 1 |
| Fasan, O | 1 |
| Balleisen, L; Basara, N; Behre, G; Casper, J; Christopeit, M; Ganser, A; Hinke, A; Hinke, R; Kahl, C; Koenigsmann, M; Metzner, B; Mohren, M; Niederwieser, D; Reichle, A; Sayer, HG; Stadler, M; Theurich, S; Uharek, L | 1 |
| Bal, C; Gulbas, Z; Ozkan, HA | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Kato, K | 1 |
| Barosi, G; Billio, A; Corradini, P; Gallamini, A; Marchetti, M; Pileri, S; Pimpinelli, N; Rossi, G; Tura, S; Zinzani, PL | 1 |
| Ancochea, Á; Fernández-Rodriguez, C; García-Pallarols, F; Gimeno, E; Salar, A; Sánchez-González, B | 1 |
| Abou Mourad, Y; Barnett, MJ; Broady, RC; Connors, JM; Forrest, DL; Gascoyne, RD; Gerrie, AS; Hogge, DE; Karsan, A; Nantel, SH; Narayanan, S; Nevill, TJ; Power, MM; Savage, KJ; Sehn, LH; Shepherd, JD; Slack, GW; Song, KW; Sun, H; Sutherland, HJ; Toze, CL; Villa, D | 1 |
| Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X | 1 |
| Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM | 1 |
| Alamoudi, S; Anglin, P; Baetz, T; Chen, BE; Cheung, M; Couban, S; Crump, M; Djurfeldt, MS; Hay, AE; Ismail, WS; Kouroukis, CT; Kuruvilla, J; Luminari, S; MacDonald, DA; Meyer, RM; Olney, HJ; Seftel, M; Shepherd, L; Turner, AR | 1 |
| Altuntaş, F; Civriz Bozdağ, S; Durgun, G; Esbah, O; Kaya, A; Kayıkçı, Ö; Kocubaba, Ş; Şirinoğlu Demiriz, I; Tekgündüz, E; Tetik, A | 1 |
| Ambinder, RF; Epeldegui, M; Lee, JY; Magpantay, LI; Martínez, AC; Martínez-Maza, O; Mitsuyasu, R; Regidor, D; Sparano, JA; Widney, DP | 1 |
| Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B | 1 |
| Ahn, JY; Cho, EK; Cho, EY; Hong, J; Hwang, I; Lee, JH; Park, J; Park, S; Shin, DB | 1 |
| Abramson, JS; Cassaday, R; Chavez, JC; Fenske, TS; Gandhi, M; Jaso, J; Landsburg, DJ; Medeiros, LJ; Nabhan, C; Petrich, AM; Press, O; Shah, N; Sohani, AR; Song, K; Yang, DT; Zelenetz, AD | 1 |
| Ardeshna, K; Halsey, R; Kayani, I; Skoura, E; Wan, S | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Fino, N; Gruber, L; Hurd, D; Kennedy, L; Lamar, ZS; Morris, BB; Palmer, J; Raetskaya-Solntseva, O; Vaidya, R; Zamkoff, K | 1 |
| Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R | 1 |
| Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Burger, E; Ferreri, AJ; Finke, J; Fricker, H; Fritsch, K; Grishina, O; Ihorst, G; Illerhaus, G; Kasenda, B; Mikesch, K; Schorb, E; Valk, E; Zucca, E | 1 |
| Ando, M; Ando, Y; Emi, N; Hayashi, T; Inaguma, Y; Ito, K; Okamoto, A; Okamoto, M; Tomono, A; Tsuge, M; Yamada, S | 1 |
| Arima, N; Fukunaga, A; Hyuga, M; Iwasaki, M; Kishimoto, W; Maesako, Y; Nakae, Y | 1 |
| Andresen, S; Bolwell, BJ; Carlstrom, KD; Dean, R; Gerds, A; Hamilton, B; Hill, BT; Jagadeesh, D; Kalaycio, M; Liu, H; Majhail, NS; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Craig, MD; Cumpston, A; D'Souza, A; Dhakal, B; Eastwood, D; Esselman, J; Fenske, TS; Hamadani, M; Hari, P; Kanate, AS; Pasquini, MC; Shillingburg, A; Veltri, LW; Watkins, K | 1 |
| Clemmons, AB; DeRemer, DL; Evans, SS; Gandhi, AS | 1 |
| Hao, X; He, Z; Hong, T; Huang, F; Lei, J; Lu, Y; Sun, H; Yang, L; Zeng, J | 1 |
| Cantú-Rodríguez, O; De la Garza-Salazar, F; García-Sepúlveda, R; Gómez-Almaguer, D; González-Llano, Ó; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Mancias-Guerra, C; Salazar-Riojas, R | 1 |
| Cortes, JE; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Khouri, M; Khoury, JD; Ko, H; O'Brien, SM; Pierce, S; Ravandi, F; Short, NJ; Thomas, DA; Thompson, PA; Verstovsek, S; Wierda, WG | 1 |
| Bai, LY; Chang, MS; Chao, SC; Chen, CC; Lin, JS; Liu, JH | 1 |
| Birkmann, J; Bodenstein, H; Clemens, M; Fuchs, R; Hänel, M; Hensel, M; Peter, N; Pfreundschuh, M; Reiser, M; Zeynalova, S; Ziepert, M; Zwick, C | 1 |
| Bhattacharya, S; Clamp, AR; Pettengell, R; Radford, JA; Ryder, WD | 1 |
| Damon, L; Damon, LE; Gaensler, K; Kaplan, L; Linker, C; Martin, T; Rubenstein, J | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S | 1 |
| Eom, HS; Kang, HJ; Kim, HY; Kim, SJ; Kim, WS; Lee, DH; Nam, SH; Suh, C; Sym, SJ | 1 |
| Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
| Jonathan, F | 1 |
| Aurer, I; Labar, B; Mitrović, Z; Mrsić, M; Nemet, D; Nola, M; Radman, I; Santek, F; Sertić, D; Serventi-Seiwerth, R; Stern-Padovan, R | 1 |
| Fang, JH; Jiang, W; Liang, C; Qiu, FE; Shen, Y; Xiong, XD; Zhuang, SM | 1 |
| Cui, XZ; Hao, XS; Li, LF; Li, W; Liu, PF; Liu, XM; Qiu, LH; Wang, HQ; Zhang, HL | 1 |
| Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
| Petit, J; Petit, T; Saint, F; Sénéchal, C | 1 |
| Bairey, O; Lazar, AD; Shaklai, M; Shpilberg, O | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S | 1 |
| Chang, JH; Cheong, JW; Hong, SJ; Kim, JS; Kim, KM; Kim, SJ; Lee, HW; Lee, ST; Min, YH | 1 |
| Fujii, N; Harada, M; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, K; Nishimori, H; Shinagawa, K; Takenaka, K; Tanimoto, M | 1 |
| Clarke, SJ; Cunningham, D; Dent, O; Robertson, G; Sharma, R; Smith, P | 1 |
| Abdallah, FK; Ayers, LW; Bako, J; Banura, C; Black, J; Fu, P; Johnson, JL; Kakembo, J; Katongole-Mbidde, E; Lederman, MM; Meyerson, HJ; Mwanda, WO; Ness, A; Onyango, CA; Orem, J; Remick, SC; Reynolds, S; Subbiah, V; Wabinga, H; Whalen, CC | 1 |
| Cheng, AL; Kuo, SH; Lin, ZZ; Yang, SH | 1 |
| Avitia, S; Hamilton, JS; Osborne, RF | 1 |
| Batár, P; Kiss, A; Kovácsné Kovács, E; Rejto, L; Reményi, G; Sípos, T; Szarvas, M; Szász, R; Udvardy, M; Váróczy, L | 1 |
| Chott, A; Drach, J; Fridrik, MA; Geissler, D; Greil, R; Hausmaninger, H; Krieger, O; Lang, A; Michlmayr, G; Oberaigner, W; Ulsperger, E | 1 |
| Jingwei, J; Qiong, Z; Ruofan, H; Xiaohua, L; Xinli, Z; Zhaohui, C | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Onur, H; Samur, M; Senler, FC | 1 |
| Andresen, S; Bolwell, BJ; Copelan, EA; Curtis, J; Dean, RM; Kalaycio, ME; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, RM; Sweetenham, JW | 1 |
| Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L | 1 |
| Baldini, L; Barbolini, E; Brugiatelli, M; Dell'Olio, M; Dondi, A; Federico, M; Giglio, G; Gobbi, PG; Luminari, S; Mannina, D; Merli, F; Polimeno, G; Stelitano, C | 1 |
| Bishop, MR; Dean, RM; Fowler, DH; Gress, RE; Odom, J; Pavletic, SZ; Pollack, SM; Sportes, C; Steinberg, SM | 1 |
| Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J | 1 |
| Butler, JB; Cooke, A; Demers, A; Liu, HW; Nugent, Z; Rubinger, M; Schroeder, G; Seftel, MD; Szwajcer, D | 1 |
| Brockmöller, J; Hoffmann, M; Kreuz, M; Kube, D; Loeffler, M; Pfreundschuh, M; Schirmer, MA; Trümper, L; Tzvetkov, MV; Wojnowski, L; Ziepert, M | 1 |
| Dunleavy, K; Tay, K; Wilson, WH | 1 |
| Ali, ZB; Ben Othmen, T; Bouaouina, N; Daoud, J; Elloumi, M; Ghannem, H; Laatiri, MA; Maalej, M; Meddeb, B; Msadek, F; Toumi, N | 1 |
| Kiewe, P; Thiel, E | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F | 1 |
| Behm, FG; Graham, K; Hale, GA; Howard, SC; Hudson, MM; Kaste, S; Krasin, MJ; Kun, LE; Lowe, E; Mahmoud, H; Metzger, ML; Onciu, M; Pui, CH; Razzouk, BI; Rencher, R; Ribeiro, RC; Sandlund, JT; Zhou, Y | 1 |
| Cairo, MS; Gross, TG; Harris, RE; Harrison, L; Henry, MM; Lynch, J; Perkins, SL; Smith, LM; Termuhlen, AM; Vlachos, A; Warkentin, P | 1 |
| Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C | 1 |
| Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Abonour, R; Baute, J; Cox, E; Farag, SS; Jones, D; Kane, K; Nelson, RP; Robertson, MJ; Schwartz, JE; Secrest, A; Srivastava, S; Sullivan, C; Wood, LL | 1 |
| Berthou, C; Deconinck, E; Delwail, V; François, S; Gastinne, T; Gyan, E; Milpied, N; Monjanel, H; Moreau, A; Perrodeau, E | 1 |
| Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; O'Donnell, M; Palmer, JM; Popplewell, L; Senitzer, D; Thomas, S; Tsai, NC; Zain, J | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Ballanti, S; Dammacco, F; Di Ianni, M; Falzetti, F; Iodice, G; Martelli, MF; Minelli, O; Reale, A; Ria, R; Serio, G; Vacca, A | 1 |
| Cavallin-Stahl, E; Glass, B; Haenel, M; Kaiser, U; Loeffler, M; Pfreundschuh, M; Schmitz, N; Truemper, L; Wolf, M; Zeynalova, S | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Barzał, J; Gawroński, K; Młot, B; Oborska, S; Rzepecki, P; Szczylik, C; Waśko-Grabowska, A | 1 |
| Benson, W; George, B; Hertzberg, MS | 1 |
| Avigdor, A; Avivi, I; Levi, I; Nagler, A; Or, R; Patachenko, P; Rowe, JM; Shimoni, A; Yeshurun, M; Zwas, T | 1 |
| Castillo, JJ; Echenique, IA | 1 |
| Asaka, M; Imamura, M; Ito, S; Morita, A; Murata, N; Ogasawara, R; Sasaki, J; Senoo, N; Tanaka, J; Tsutsumi, Y | 1 |
| Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
| Brown, JM; Fan, AC; Felsher, DW; Fischbein, NJ; Howard, W; Hsieh, RW; McClellan, JS; To, CA | 1 |
| Harigae, H; Hirokawa, M; Ishida, Y; Ishizawa, K; Ito, J; Kameoka, Y; Kato, Y; Murai, K; Noji, H; Sasaki, O; Sawada, K; Shichishima, T; Tajima, K; Takahashi, N | 1 |
| Cooney, JP; Kruger, PC; Turner, JH | 1 |
| Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J | 1 |
| Armistead, PM; Brown, PM; Coghill, JM; Essenmacher, A; Gabriel, DA; Goyal, R; Irons, R; Rao, KV; Sarantopoulos, S; Serody, JS; Sharf, A; Shea, TC; Whitley, J; Wood, WA | 1 |
| Ahn, HS; Kang, HJ; Kim, H; Lee, JW; Park, JD; Park, KD; Shin, HY; Yoon, JH | 1 |
| Atalla, A; Borges dos Santos, K; Hallack Neto, AE | 1 |
| Hamaguchi, H; Morita, Y; Nagata, K; Yamamoto, K | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E | 1 |
| Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ | 1 |
| Cassileth, P; Habermann, T; Manalo, J; Nazeer, T; Sparano, JA; Traynor, AE; Weller, E | 1 |
| Aitini, E; Alinari, L; Baccarani, M; Ciccone, F; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Lauria, F; Lauta, VM; Mannina, D; Mazza, P; Moretti, L; Pavone, E; Stefoni, V; Storti, S; Tani, M; Tura, S; Volpe, E; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Büchler, T; Ferra, C; Grañena, A; Montanya, E; Virgili, N | 1 |
| Fukuno, K; Goto, H; Hara, T; Kanemura, N; Kasahara, S; Moriwaki, H; Oyama, M; Sawada, M; Shimizu, M; Takami, T; Tsurumi, H; Yamada, T; Yoshikawa, T | 1 |
| Altés, A; Escoda, L; Guardia, R; López-Guillermo, A; Martino, R; Montserrat, E; Perea, G; Ribera, JM; Salar, A; Sierra, J | 1 |
| Choi, CW; Kim, BS; Kim, JS; Kim, YH; Paek, CW; Seo, JH; Shin, SW | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Couban, S; Crump, M; Eisenhauer, E; Gluck, S; Hoskins, P; Maksymiuk, A; Matthews, S; Meyer, R; Rudinskas, L; Zanke, B | 1 |
| Aurer, I; Bogdanić, V; Duraković, N; Kovacević-Metelko, J; Labar, B; Mikulić, M; Mrsić, M; Nemet, D; Radman, I; Sertić, D; Zupancić-Salek, S | 1 |
| Andresen, S; Bernhard, L; Bolwell, BJ; Kalaycio, M; Kohuth, J; Kuczkowski, E; Lomax, R; Mendiola, S; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Angrilli, F; Di Lorenzo, R; Di Marzio, A; Fioritoni, G; Liberatore, E; Pennese, E | 1 |
| Fisher, RI | 2 |
| Abel, U; Baudis, M; Birkmann, J; Bischoff, HG; Franke, A; Grundeis, M; Havemann, K; Hossfeld, DK; Kaiser, U; Karakas, T; Kneba, M; Köppler, H; Krahl, D; Mantovani, L; Mesters, RM; Metzner, B; Müller, P; Parwaresch, R; Pfab, R; Pfreundschuh, M; Reiser, M; Rothmann, F; Schmalenberg, H; Schmitz, N; Schumacher, K; Steinhauer, EU; Trümper, L; Uebelacker, I; von Seydewitz, CU | 1 |
| Emmanouilides, C; Grody, W; Lill, M; Rosen, P; Rosenfelt, F; Telatar, M; Territo, M | 1 |
| Altundağ, MK; Baltali, E; Barişta, I; Celik, I; Güler, N; Güllü, I; Kansu, E; Kars, A; Ozişik, Y; Oztürk, MA; Tekuzman, G; Türker, A; Yalçin, S | 1 |
| Southcott, BM; Stewart, AJ | 1 |
| Afanas'ev, BV; Alekseeva, IuA; Medvedeva, NV; Mikhaĭlova, NB; Zaritskiĭ, AIu; Zubarovskaia, LS | 3 |
| Al Awadi, S; Al Shemmari, S; Bajciova, V; Mottl, H; Nemec, J | 1 |
| Crump, M; Emmanouilides, C; Flinn, I; Frankel, S; Hackett, J; Lazarus, H; Liang, BC; Lovelace, W; Moore, J; Schenkein, D; Vose, JM | 1 |
| Arellano-Rodrigo, E; Bessell, EM; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B | 1 |
| Ballen, K; Becker, PS; Clark, Y; Emmons, RV; Levy, W; Liu, Q; Rossi, HA; Westervelt, P | 1 |
| Briggs, A; Chow, HH; Dorr, RT; Kintzel, P; List, A; Meyers, R | 1 |
| Munck, JN | 1 |
| Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Lin, XB; Liu, DG; Sun, XF; Wang, W; Xia, ZJ; Xu, GC; Xu, RH; Zhang, L; Zhou, ZM | 1 |
| Hamlin, P; Kewalramani, T; Moskowitz, CH; Nimer, S; Yahalom, J; Zelenetz, AD | 1 |
| Benson, W; Bradstock, KF; Crombie, C; Gottlieb, D; Hertzberg, MS; Taper, J | 1 |
| Sneller, V; Vose, J | 1 |
| Zinzani, PL | 1 |
| Bunin, N; Cotte, J; Gregson, B; Grupp, S; June, CH; Laport, GG; Levine, BL; Liebowitz, DN; Luger, SM; Porter, DL; Rivers, P; Schuster, SJ; Stadtmauer, EA; Strobl, FJ; Vonderheide, RH; Zheng, Z | 1 |
| Griniūte, R; Pileckyte, M | 1 |
| Bittner, S; Kloess, M; Loeffler, M; Pfreundschuh, M; Reiser, M; Rudolph, C; Schmalenberg, H; Schmits, R; Truemper, L; Wunderlich, A | 1 |
| Amess, J; Cornelius, V; Delves, T; Fitzgibbon, J; Last, KW; Lister, TA; Norton, A; Rohatiner, AZ; Sieniawska, C; Wilson, A | 1 |
| Greco, FA; Hainsworth, JD; Lamb, MR; Litchy, S; Rodriguez, GI; Scroggin, C | 1 |
| Fuks, J; Hopkins, U; Negassa, A; Perez, A; Ratech, H; Salman, H; Sparano, JA; Villani, G; Wiernik, PH | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T | 1 |
| Boccadoro, M; Caracciolo, D; Cuttica, A; Dell'Aquila, M; Di Nicola, M; Gianni, AM; Ladetto, M; Magni, M; Marinone, C; Pileri, A; Rosace, M; Tarella, C; Zallio, F | 1 |
| Bornhäuser, M; Ehninger, G; Illmer, T; Kroschinsky, F; Renner, U; Schaich, M; Schimmelpfennig, C; Schimming, C; Schleyer, E; Trümper, L | 1 |
| Mead, G; Woodcock, J; Young, C | 1 |
| Chin, K; Furuta, N; Hatake, K; Itoh, Y; Mishima, Y; Mizunuma, N; Nagasaki, E; Shinozaki, E; Takahashi, S; Terui, Y; Tokutome, N; Usui, N | 1 |
| Abrey, LE; Anderson, ND; Caron, D; Correa, DD; Crump, M; DeAngelis, LM; Forsyth, P; Mason, WP; Moskowitz, CH; Nimer, SD; Paleologos, N; Stewart, D; Zelenetz, A | 1 |
| Dekker, AW; Mandigers, CM; Meijerink, JP; Raemaekers, JM; Schattenberg, AV; Verdonck, LF | 1 |
| Chen, SP; Wu, DS; Zhao, XL | 1 |
| Davidson, KL; Devaney, MB; Dunlop, DJ; Johnson, PR; Mackie, MJ; Rogers, SY; Thomas, RV; Tighe, JE | 1 |
| Hehn, ST; Miller, TP | 1 |
| Atkinson, ME; Baranski, B; Gangnon, R; Juckett, M; Kahl, BS; Longo, WL; McCoy, AG; Mitchell, T; Smith, EP | 1 |
| Ambrosetti, A; Cabras, MG; Di Vito, F; Fioritoni, G; Gabbas, A; Gallamini, A; Gallo, E; Gargantini, L; Gottin, L; Lazzarino, M; Menestrina, F; Morra, E; Orlandi, E; Palestro, M; Pasini, F; Paulli, M; Pizzolo, G; Pizzuti, M; Rossi, G; Secchi, S; Tarella, C; Tecchio, C; Todeschini, G; Vitolo, U | 1 |
| Abrey, LE; DeAngelis, LM; Lai, R; Rosenblum, MK | 1 |
| Gisselbrecht, C; Mounier, N | 1 |
| Aleksza, M; Gergely, L; Illés, A; Ponyi, A; Sipka, S; Szegedi, G; Váróczy, L | 1 |
| Adams, PT; Ayash, LJ; Dawson, LA; Eisbruch, A; Lichter, AS; Ratanatharathorn, V; Reynolds, CM; Saito, NG; Schipper, MJ; Silver, SM; Uberti, JP | 1 |
| Aversa, S; Candela, M; Centurioni, R; Chisesi, T; Congiu, M; De Souza, C; Gennaro, M; Nardi, V; Olivieri, A; Patti, C; Rubagotti, A; Santini, G; Tedeschi, L; Truini, M | 1 |
| Blair, IA; Boston, R; Felix, CA; Moate, P; Pang, S; Scavuzzo, J; Zheng, N | 1 |
| Champlin, R; Devine, S; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Peace, D; Sosman, J; Stock, W; Van Besien, K; Wadehra, N; Wickrema, A | 1 |
| Cailliot, C; Fouillard, L; Gorin, NC; Isnard, F; Labopin, M; Laporte, JP; Lesage, S; Najman, A; Yeshurun, M | 1 |
| Ai, B; Han, XH; He, XH; Liu, P; Shi, YK; Yang, JL; Zhang, CG | 1 |
| Bertz, H; Fetscher, S; Finke, J; Lange, W; Waller, CF; Zeiser, R | 1 |
| Bertè, R; Bertini, M; Botto, B; De Paoli, A; Federico, M; Luminari, S; Merli, F; Mozzana, R; Pizzuti, M; Quintana, G; Stelitano, C; Trottini, M | 1 |
| Aloulou, S; Cainap, C; Carde, P; Chalhoub, B; Fermé, C; Jabbour, E; Ribrag, V; Suzan, F; Toumi, N | 1 |
| Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B; Schiavone, EM; Viola, A | 1 |
| Acquatella, G; Carneiro, M; García, R; Gómez, R; Hernández, M; Insausti, CL; Nouel, A; Santos, S | 1 |
| Barrier, R; Buckley, P; DeCastro, CM; Gockerman, JP; Ibom, VK; Laney, R; Moore, JO; Niedzwieki, D; Rizzieri, DA; Rumbaugh, H; Stevenson, D; Talbot, J | 1 |
| Al-Izzi, M; Constantinou, J; McNicholas, TA; Nitkunan, T | 1 |
| Armitage, JO; Bierman, PJ; Bociek, G; Enke, C; Hankins, J; Lynch, JC; Vose, JM | 1 |
| Aydin, F; Bektas, O; Kavgaci, H; Ozdemir, F; Yavuz, AA; Yavuz, MN; Yilmaz, M | 1 |
| Baek, JH; Kim, DH; Kim, JG; Lee, KB; Park, TI; Sohn, SK | 1 |
| Bajor, DL; Bedi, T; Cooper, BW; Creger, RJ; Fox, RM; Fu, P; Gerson, SL; Koc, ON; Laughlin, MJ; Lazarus, HM; Payne, J; Wadhwa, PD | 1 |
| Klasa, RJ | 1 |
| Chi, HS; Huh, J; Kang, YK; Kim, EK; Kim, MW; Kim, S; Kim, SB; Kim, SH; Kim, SW; Lee, J; Lee, JL; Park, CJ; Suh, C | 1 |
| Alterini, R; Bernardi, F; Bosi, A; Carrai, V; Longo, G; Nassi, L; Rigacci, L | 1 |
| Carde, P; Ferme, C; Girinsky, T; Koscielny, S; Lapusan, S; Ribrag, V | 1 |
| Fujino, H; Hayashi, K; Hirai, M; Hirose, A; Ishii, K; Katsurada, T; Kitajima, H; Kitayama, H; Mugitani, A; Ohta, T; Shigeki, T; Teshima, H; Urase, F; Yagi, T; Yamamoto, Y | 1 |
| Blayney, DW; Cruickshank, SE; Johnson, DH; McGuire, BW | 1 |
| Rao, PS | 1 |
| Kluin, PM; Kluin-Nelemans, HC; Mackenzie, MA; Ossenkoppele, GJ; Schouten, HC; Sonneveld, P; Steijaert, MM; van der Holt, B; van Imhoff, GW; Van't Veer, MB; Verdonck, LF; Wijermans, PW | 1 |
| Dong, M; Feng, FY; He, XH; Huang, DZ; Liu, P; Shi, YK; Yang, JL; Yang, S; Zhang, CG; Zhang, P; Zhou, SY | 1 |
| Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A | 1 |
| Anderson, AL; Dagis, A; Falk, P; Forman, S; Fung, H; Kirschbaum, M; Kogut, N; Krishnan, A; Kwok, C; Molina, A; Nademanee, A; Nakamura, R; O'donnell, M; Parker, P; Popplewell, L; Pullarkat, V; Raubitschek, A; Rodriguez, R; Sahebi, F; Smith, D; Smith, E; Snyder, D; Spielberger, R; Stein, A; White, C; Yamauchi, D; Zain, J | 1 |
| Arnaud, P; Bocaccio, C; Bourhis, JH; Carde, P; Ferme, C; Jabbour, E; Koscielny, S; Peslin, N; Ribrag, V; Vantelon, JM | 1 |
| Błoński, JZ; Chojnowski, K; Kasznicki, M; Robak, T; Szmigielska-Kapłon, A | 1 |
| Chamorey, E; Delwail, V; Fabbro, M; Foussard, C; Gressin, R; Harrousseau, JL; Lepeu, G; Maisonneuve, H; Peyrade, F; Richard, B; Rossi, JF; Thyss, A; Vilque, JP | 1 |
| De Silva, CR; Lansigan, E; Locke, R; Negassa, A; Sparano, JA; Wiernik, PH | 1 |
| Kansu, E; Kars, A; Koc, Y; Oyan, B; Ozdemir, E; Tekuzman, G; Turker, A | 1 |
| Ficker, ES; Hungria, VT; Maranhão, RC; Mesquita, CH; Pinheiro, KV; Valduga, CJ | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Abonour, R; Cornetta, K; Fineberg, NS; Hromas, R; Nelson, RP; Robertson, MJ | 1 |
| Arts, K; Brandwein, J; Crump, M; Dotten, DA; Foote, M; Franssen, E; Routy, JP; Sawka, CA; Shepherd, FA; St-Louis, J; Taylor, M; Walker, IR | 1 |
| Ala-Kopsala, M; Hartikainen, J; Husso-Saastamoinen, M; Jantunen, E; Kuittinen, T; Nousiainen, T; Sipola, P; Vuolteenaho, O | 1 |
| Beitler, B; Bellesso, M; Chamone, D; de Almeida Macedo, MC; Dias, LC; Dorlhiac-Llacer, PE; Dulley, FL; Neto, AE; Pereira, J; Pracchia, LF | 1 |
| Abate, G; Comella, P; Di Finizio, G; Fiore, M; Zarrilli, D | 1 |
| Diehl, V; Engert, A; Reiser, M; Rödel, S | 1 |
| Aranha, FJ; Baldissera, RC; De Souza, CA; Lorand-Metze, I; Maiolino, A; Miranda, EC; Moraes, AA; Nucci, M; Pagnano, KB; Ruiz, MA; Simões, BP; Vigorito, AC | 1 |
| Assouline, S; Carriere, P; Laneuville, P; Shustik, C; Sylvestre, MP | 1 |
| Fukuda, H; Fukuhara, S; Hirose, Y; Hotta, T; Kawano, F; Kikuchi, M; Mizoroki, F; Nakata, M; Nasu, K; Ohno, Y; Sano, M; Sawada, K; Shimoyama, M; Taniwaki, M; Tobinai, K; Togawa, A; Toki, H; Uozumi, K | 1 |
| Fujimaki, K; Fujisawa, S; Fujita, H; Harano, H; Hashimoto, C; Ishigatsubo, Y; Kanamori, H; Kodama, F; Koharazawa, H; Maruta, A; Motomura, S; Sakai, R; Tomita, N | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Engel, C; Loeffler, M; Scholz, M | 1 |
| Al-Kgodary, T; Mabed, M | 1 |
| Burton, C; Cunningham, D; Dyer, MJ; Hancock, B; Hoskin, P; Jack, A; Linch, D; MacLennan, K; Milligan, D; Mouncey, P; Qian, W; Smith, P; Webb, A | 1 |
| Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Artibani, W; Boscolo Berto, R; El Mazloum, R; Fassina, A; Gottardo, F | 1 |
| Bo, J; DA, WM; Li, HH; Wang, QS; Wang, SH; Wu, XX; Yu, L; Zhao, Y | 1 |
| Blume, KG; Horning, SJ; Johnston, LJ; Laport, GG; Law, LY; Lowsky, R; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Wong, RM | 1 |
| Aggarwal, C; Carabasi, MH; Gupta, S; Katz, RO; Nance, AG; Salzman, DE; Saylors, GB; Tilden, AB; Vaughan, WP | 1 |
| Dabbas, B; Ford, CD; Gabor, F; Morgan, R | 1 |
| Ala-Kopsala, M; Hartikainen, J; Jantunen, E; Kuittinen, T; Mussalo, H; Nousiainen, T; Vanninen, E; Vuolteenaho, O | 1 |
| Seymour, JF; Stern, CJ | 1 |
| Acholonu, S; Anderlini, P; Champlin, R; Couriel, DR; De Lima, M; Donato, ML; Giralt, S; Hosing, C; Khouri, IF; Körbling, M; McMannis, J; Okoroji, GJ; Saliba, RM | 1 |
| Bunworasate, U; Intragumtornchai, T; Nakorn, TN; Rojnuckarin, P | 1 |
| Chou, T; Han, LN; Hirose, T; Imai, Y; Ishiguro, T; Zhou, J | 1 |
| Aoki, S; Hirano, M; Kohori, M; Miura, I; Niitsu, N; Okamoto, M | 1 |
| Huh, J; Jeong, YP; Kim, S; Kim, SB; Kim, SW; Ko, OB; Koo, JE; Lee, D; Lee, JL; Park, SH; Suh, C | 1 |
| Boehme, V; Kaiser, U; Kloess, M; Loeffler, M; Pfreundschuh, M; Schmitz, N; Zeynalova, S | 1 |
| Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J | 1 |
| Guan, ZZ; He, YF; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Lin, TY; Lu, TX; Xia, YF; Xian, CG; Zhang, YJ | 1 |
| Bo, LJ; Chen, YH; Jin, XP; Liang, AB; Liu, B; Wang, F | 1 |
| Alvarez Z, M; Bertín C-M, P; Besa de C, P; Bustos C, M; Lira V, P; Ocqueteau T, M; Ramírez V, P | 1 |
| Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE | 1 |
| Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A | 1 |
| Atta, J; Chow, KU; Hoelzer, D; Martin, H; Mitrou, PS; Weidmann, E | 1 |
| Bakshi, A; Gujral, S; Gupta, S; Nair, R; Parikh, P; Prabhash, K; Sengar, M | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Avilés, A; Castañeda, C; Cleto, S; Nambo, MJ | 1 |
| Akutsu, M; Inoue, K; Izumi, T; Kano, Y; Katano, S; Kobayashi, H; Masuda, Y; Muroi, K; Nagashima, T; Ohmine, K; Ozawa, K; Shirai, T; Takagi, S; Tsunoda, S; Ueda, M; Ueda, T | 1 |
| Chen, ZC; Li, QB; Tang, XQ; Wang, HX; You, Y; Zhao, ZG; Zou, P | 1 |
| Ehninger, G; Friedrichsen, K; Haenel, M; Kroschinsky, FP; Mueller, J; Prondzinsky, R; Pursche, S; Schleyer, E | 1 |
| Bajor, DJ; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Koç, ON; Laughlin, MJ; Lazarus, HM; van Heeckeren, WJ; Wadhwa, PD; Xu, Z | 1 |
| Bae, SH; Chae, YS; Eom, HS; Jung, JS; Kim, DH; Kim, HJ; Kim, JG; Kim, SJ; Kim, WS; Lee, JJ; Shin, HJ; Sohn, SK; Suh, C; Yang, DH | 1 |
| Guang, ZZ; Jiang, WQ; Li, ZM; Liu, ZC; Yang, DJ; Zhou, JM; Zhu, XF; Zhu, ZY | 1 |
| Herrmann, M; Kneer, H; König, J; Pfreundschuh, M; Widmann, T | 1 |
| Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S | 1 |
| Bentz, M; Dührsen, U; Einsele, H; Lengfelder, E; Loeffler, M; Mergenthaler, HG; Mesters, R; Pflüger, KH; Pfreundschuh, M; Rübe, C; Schmitz, N; Trümper, L; Vrieling, T; Zeynalova, S; Zwick, C | 1 |
| Bentz, M; Graeven, U; Hasenclever, D; Hoffmann, M; Hohloch, K; Liersch, R; Loeffler, M; Metzner, B; Mohren, M; Pfreundschuh, M; Schmits, R; Trümper, L; Wruck, U; Ziepert, M; Zwick, C | 1 |
| Fefer, A; Fisher, RI; Forman, SJ; Leblanc, M; Nademanee, AP; Petersdorf, SH; Press, OW; Stiff, PJ; Thompson, JA; Unger, JM | 1 |
| Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S | 1 |
| Basecke, J; Becker, A; Glass, B; Griesinger, F; Haase, D; Podleschny, M; Schmitz, N; Schwiers, I; Schwiers, R; Seiffert, E; Trumper, L | 1 |
| Geng, L; Li, X; Song, M; Wang, RL; Zang, WP; Zhang, MZ | 1 |
| Abali, H; Budakoğlu, B; Güler, T; Oksüzoğlu, B; Ozet, G; Urün, Y; Yildirim, N; Zengin, N | 1 |
| Aversa, SML; Bianco, A; Errante, D; Salvagno, L | 1 |
| Bron, D; Cahn, JY; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Harousseau, JL; Philip, T; Somers, R; Sonneveld, P; Van der Lelie, H | 1 |
| Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H | 1 |
| Amadori, S; Avvisati, G; Coluzzi, S; Giovannini, M; Guglielmi, C; Mandelli, F; Martelli, M; Torromeo, C | 1 |
| Chang, J; Crowther, D; Morgenstern, GR; Pettengell, R; Radford, JA; Rowlands, M; Scarffe, JH; Testa, NG; Woll, PJ; Young, R | 1 |
| Cropper, T; Glenn, LD; Klumpp, TR; Macdonald, JS; Malaspina, DR; Mangan, KF; Mullaney, M | 1 |
| Abe, T; Fujii, H; Kuzuyama, Y; Nakagawa, H; Sakabe, H; Sonoda, Y | 1 |
| Clark, S; Crowther, D; Radford, JA; Shalet, SM | 1 |
| Anglin, P; Brandwein, JM; Strauss, BA | 1 |
| Ezaki, K; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Sobue, R; Tsuzuki, M; Wakita, M | 1 |
| Allen, PK; Cabanillas, FF; Fuller, LM; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Swan, F; Tucker, SL; Velasquez, WS | 1 |
| Deakin, D; Harris, M; James, RD; Lister, TA; Radford, JA; Rohatiner, AZ; Stansfeld, AG; Swindell, R; Whelan, JS; Wilkinson, PM | 1 |
| Byrne, A; Carney, DN; Corbally, N; Dervan, PA; Grogan, L | 1 |
| Cabanillas, F; Hagemeister, FB; Lee, MS; McLaughlin, P; Pate, O; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Younes, A | 1 |
| Coltman, CA; Dahlberg, S; Fisher, RI; Gaynor, ER; Glick, JH; Grogan, TM; Miller, TP; Mize, EM; Oken, MM | 2 |
| Bron, D; Carde, P; de Bock, R; De Wolf-Peeters, C; Delmer, A; Keunig, JJ; Keuning, JJ; Somers, R; Thomas, J; Tirelli, U | 1 |
| Bender, JG; Coon, J; George, S; Ghalie, R; Kaizer, H; Lee, W; Lum, L; McLeod, B; Unverzagt, KL; Van Epps, D | 1 |
| Chisesi, T; Congiu, AM; Contu, A; Coser, P; Porcellini, A; Rubagotti, A; Salvagno, L; Santini, G; Sertoli, MR; Vespignani, M | 1 |
| Ben-Dayan, D; Djaldetti, M; Floru, S; Mittelman, M | 1 |
| Baldini, L; Butti, C; Cassi, E; Ceriani, A; Confalonieri, C; De Paoli, A; Lombardi, F; Montalbetti, L; Pisoni, GB; Scandolaro, L | 1 |
| Lishner, M; Slingerland, J; Sutcliffe, SB; Theresa, C | 1 |
| Angus, B; Carey, P; Evans, RG; Jackson, GH; Lennard, AL; Lucraft, H; Proctor, SJ; Taylor, PR | 1 |
| DeVita, VT; Duffey, PL; Fisher, RI; Hubbard, SM; Jaffe, ES; Longo, DL; Raffeld, M; Wittes, RE; Young, RC | 1 |
| Dagis, AC; Molina, A; Nademanee, A; O'Donnell, MR; Parker, PM; Schmidt, GM; Smith, EP; Sniecinski, I; Snyder, DS; Stein, AS | 1 |
| Hirano, M | 1 |
| Bosly, A; Coiffier, B; D'Agay, MF; Gisselbrecht, C; Haioun, C; Herbrecht, R; Lepage, E; Morel, P; Nouvel, C; Tilly, H | 1 |
| Brittinger, G; Engelhard, M; Heinz, R; Huhn, D; Nerl, C; Parwaresch, R; Siegert, W; Tiemann, M | 1 |
| Avilés, A; Díaz-Maqueo, JC; García, EL; Nambo, MJ; Talavera, A | 1 |
| Begley, CG; Boyd, AW; Grigg, AP; Lickliter, JD; Szer, J | 1 |
| Bertini, M; Botto, B; Freilone, R; Gavarotti, P; Levis, A; Orlandi, E; Orsucci, L; Pini, M; Pizzuti, M; Vitolo, U | 1 |
| Hahn, J; Herndier, B; Kaplan, LD; McGrath, MS; Meeker, TC; Ng, V; Shiramizu, B; Volberding, PA | 1 |
| Bassan, R; Bellavita, P; Borleri, GM; Buelli, M; Comotti, B; Cortelazzo, S; Marziali, S; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Brandi, M; De Lena, M; Ditonno, P; Lorusso, V; Marzullo, F; Pellecchia, A; Timurian, A; Ventrella, V | 1 |
| Brown, BW; Chao, NJ; Horning, SJ; Hoyle, C; Hu, WW; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR; Still, BJ | 1 |
| Dranitsaris, G; Sutcliffe, SB | 1 |
| Fujimoto, N; Higuchi, M; Kawamura, M; Kuni-Eda, Y; Kurosawa, M; Maekawa, I; Morioka, M; Ohmura, T; Okabe, M; Suzuki, S | 1 |
| Ben-Shahar, M; Epelbaum, R; Haim, N | 1 |
| Dejbakhsh-Jones, S; Ginzton, N; Greenberg, P; Kusnierz-Glaz, CR; Negrin, RS; Schriber, JR; Still, B; Strober, S | 1 |
| Amill, B; Brunet, S; Domingo-Albós, A; García-López, J; Madoz, P; Martínez, C; Mateu, R; Portos, JM; Subirà, M; Sureda, A | 1 |
| Dreger, P; Haferlach, T; Klöss, M; Loeffler, M; Löffler, H; Petersen, B; Schmitz, N | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Heinz, R; Hopfinger, G; Koller, E; Pittermann, E; Schneider, B | 1 |
| Bijnens, L; Hagenbeek, A; Kluin-Nelemans, JC; Meerwaldt, JH; Noordijk, EM; Peeters, CD; Pittaluga, S; Somers, R; Teodorovic, I; van Glabbeke, M | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 1 |
| Cairo, MS | 1 |
| Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z | 1 |
| Horie, T; Irie, T; Kura, Y; Satoh, Y; Sawada, U; Tsuboi, I | 1 |
| Abe, T; Hirao, A; Kawano, Y; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y; Watanabe, T | 1 |
| Hagemeister, FB | 1 |
| Cheson, BD; Feigal, EG | 1 |
| Greco, FA; Greer, JP; Hainsworth, JD; Johnson, DH; McMaster, ML; Stein, RS; Waits, TM; Wolff, SN | 1 |
| Urushizaki, I | 1 |
| Wu, GQ | 1 |
| Bates, S; Bryant, G; Cheson, BD; Fojo, A; Herdt, J; Jaffe, ES; Kohler, DR; Steinberg, SM; Wilson, WH; Wittes, RE | 1 |
| DeVita, VT; Longo, DL; Young, RC | 1 |
| Müller, U; Stahel, RA | 1 |
| Hara, A; Niitsu, N; Shirai, T; Umeda, M | 1 |
| Klapper, P; Morris, D; Schofield, K | 1 |
| Crowther, D; Dexter, TM; Pettengell, R; Swindell, R; Testa, NG | 1 |
| Greco, FA; Greer, JP; Hainsworth, JD; Waits, TM | 1 |
| Ezoe, A; Fujisaki, Y; Hayashi, S; Kohda, K; Nakazawa, O; Takayanagi, N; Takeda, M; Takimoto, R; Tsuji, A; Tsuji, Y | 1 |
| Bosly, A; Coiffier, B; Gisselbrecht, C; Haioun, C; Herbrecht, R; Lepage, E; Morel, P; Reyes, F; Sebban, C; Tilly, H | 1 |
| Bonnel, C; Catry-Thomas, I; Eghbali, H; Hoerni, B; Soubeyran, P | 1 |
| Fujimoto, T; Kikuchi, M; Shimizu, H; Takaue, Y; Takeda, T; Utsumi, J | 1 |
| Armitage, JO; Bierman, PJ; Gwilt, P; Kris, E; Vaughan, WP; Vose, J | 1 |
| Andersson, BS; Bellare, N; Gajewski, JL; Giralt, SA; Khouri, IF; McCarthy, P; Mehra, R; Nath, R; Przepiorka, D; van Besien, KW | 1 |
| Jacobs, P; Johnson, C; King, HS; Novitzky, N | 1 |
| Goldstone, AH; Khwaja, A; Linch, DC | 1 |
| Ballester, OF; Cooper, BW; Creger, RJ; Elfenbein, GJ; Fields, KK; Hiemenz, JH; Janssen, WE; Lazarus, HM; Perkins, JB; Zorsky, PE | 1 |
| Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW | 1 |
| Carrión, JR; García Arroyo, FR; Salinas, P | 1 |
| Dorr, RT | 1 |
| Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, A; Mills, W; Pearce, R | 1 |
| Bourdin, S; Bulabois, CE; Bureau, B; Harousseau, JL; LeTortorec, S; Mahé, B; Mahé, MA; Milpied, N; Moreau, A; Moreau, P | 1 |
| Aglietta, M; Bondesan, P; Caracciolo, D; Falda, M; Gallo, E; Gavarotti, P; Locatelli, F; Novarino, A; Paolino, F; Sanavio, F | 1 |
| Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L | 1 |
| Green, JA; Pendleton, N | 1 |
| Bajetta, E; Buzzoni, R; Colleoni, M; Nelli, P; Nolè, F | 1 |
| Chan, KW; Cole, CH; Davis, JE; Phillips, G; Pritchard, S; Rogers, PC | 1 |
| Becker, NH; Carney, D; Elkind, R; Leaf, A; Sarta, C; Shah, M; Sparano, JA; Strack, M; Valentine, ES; Wiernik, PH | 1 |
| Ascensao, JL; Berkman, E; Desforges, JF; Dixon, P; Erban, JK; Miller, KB; Schenkein, DP | 1 |
| Dorr, RT; Lauper, D | 1 |
| Blume, KG; Chao, JC; Hoppe, RT; Horning, SJ; Long, GD; Negrin, RS | 1 |
| Appelbaum, FR; Bensinger, WI; Brunvand, M; Deeg, HJ; Hansen, JA; Martin, P; Petersen, FB; Press, O; Sandmaier, B; Weaver, CH | 1 |
| Johnson, PW; Sweetenham, JW | 1 |
| Egami, K; Furusawa, S; Mikuni, C; Mori, M; Nomura, T; Shimoyama, M; Sugimoto, T; Suzuki, K; Takagi, T; Yoshida, T | 1 |
| Battista, C; Bevilacqua, N; Chiurazzi, B; Cocorocchio, E; Esposito, G; Iodice, G; Pacilio, G; Panza, N | 1 |
| Couture, F; Imrie, KR; Keating, A; Sutcliffe, SB; Turner, CC | 1 |
| Brown, AE; Crown, JP; Gulati, SC; Jurcic, JG; Koll, B; Yahalom, J | 1 |
| Greco, FA; Greer, JP; Hainsworth, JD; Young, WA | 1 |
| Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Sobue, R; Tsuzuki, M; Wakita, M | 1 |
| Muggia, FM | 1 |
| Crist, WM; Pratt, CB; Pui, CH; Rivera, GK; Santana, VM | 1 |
| Carbone, A; Errante, D; Monfardini, S; Sorio, R; Talamini, R; Tirelli, U; Zagonel, V | 1 |
| Burkes, R; Chow, W; Crump, M; Davidson, M; Goss, PE; King, M; Myers, R; Poldre, P; Rudinskas, L; Sutton, D | 1 |
| Attal, M; Canal, P; Huguet, F; Laurent, G; Pris, J; Schlaifer, D | 1 |
| Abdel-Warith, A; Berry, J; Ezzat, AA; Khalifa, F; Khan, B; Raja, MA | 1 |
| Baxter, JD; DiNubile, MJ | 1 |
| Antman, K; Ayash, L; Bierer, BE; Churchill, WH; Eder, JP; Elias, A; Gilliland, DG; Guinan, EC; Strawderman, M; Wheeler, C | 1 |
| Asayama, R; Hagimoto, N; Harada, M; Higuchi, K; Hyodo, S; Katoh, M; Ohno, Y; Takita, A; Taniguchi, S; Yamasaki, K | 1 |
| Niitsu, N | 1 |
| Ahmed, T; Chun, H; Coleman, M; Cook, P; Coombe, N; Feldman, E; Helson, L; Mittelman, A; Puccio, C | 1 |
| Birkmann, J; Eschenbach, I; Gropp, C; Holle, R; Köppler, H; Oehl, S; Pfab, R; Pflüger, KH; Steinhauer, UE; Zeller, W | 1 |
| Greco, FA; Hainsworth, JD; Hande, KR; Holzmer, M; Thompson, DS | 1 |
| Ariad, S; Bezwoda, MA; Bezwoda, WR; Dansey, R; Seymour, L | 1 |
| Capochiani, E; Caracciolo, F; Grassi, B; Papineschi, F; Petrini, M | 1 |
| Greco, FA | 1 |
| Abe, Y; Ikeda, A; Miyamoto, K; Moriya, A; Yokoyama, N; Yokoyama, T | 1 |
| Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J | 1 |
| Clark, D; Kubica, R; Neidhart, JA; Pfile, J; Rinehart, J; Stidley, C | 1 |
| de Campos, ES; Harris, M; Menasce, LP; Radford, J; Thatcher, N | 1 |
| Fukazawa, M; Hashimoto, S; Ishii, A; Kawano, E; Kogure, K; Matsuura, Y; Nakamura, H; Nishimura, M; Oh, H; Okuyama, Y | 1 |
| Siegert, W | 1 |
| Ashida, T; Ayabe, T; Maekawa, I; Namiki, M; Shibata, Y; Taruishi, M | 1 |
| Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S | 1 |
| Ashley, S; Catovsky, D; Cunningham, D; Gore, ME; Hickish, T; Mansi, J; Nicolson, V; Roldan, A; Smith, IE | 1 |
| Blanchard, CG; Eastman, AY; McSharry, JJ; Pearce, T; Portuese, E; Powell, D; Remick, SC; Wagner, H; Wighton, T; Wolf, BC | 1 |
| Ahmed, T; Chun, H; Cook, P; Coombe, N; Corbi, D; Engelking, C; Helson, L; Mittelman, A; Puccio, C; Szalyga, J | 1 |
| McKendrick, JJ; Mead, GM; Sweetenham, JW; Whitehouse, JM | 1 |
| Dorigo, A; Kwan, YL; Mansberg, R | 1 |
| Akatsuka, J; Furukawa, T; Nakazawa, S; Nishimura, K; Ohira, M; Okawa, Y; Sugita, K; Tsuchida, M | 1 |
| Ansell, SM; Falkson, G | 1 |
| Bruno, S; Cerutti, I; Corrado, C; Fernández, I; Magnasco, H; Milone, G; Pavlovsky, S; Saslavsky, J; Somoza, N | 1 |
| Gerhartz, HH; Walther, J; Wilmanns, W | 1 |
| Chisesi, T | 1 |
| Hainsworth, JD | 1 |
| Becker, N; Leaf, A; Sparano, JA; Strack, M; Valentine, ES; Wiernik, PH | 1 |
| Dobashi, N; Hirano, A; Isogai, Y; Kobayashi, T; Kuraishi, Y; Takagi, K | 1 |
| Dutcher, JP; Leaf, A; Sparano, JA; Wiernik, PH | 1 |
| Anderson, J; Budman, DR; Gottlieb, AJ; Kaplan, R; Rybak, ME; Vinciguerra, V | 1 |
| Smith, RJ; Sweetenham, JW | 1 |
| Benedetti, G; Bondesan, P; Caracciolo, D; Castellino, C; Cherasco, C; Gianni, AM; Omedé, P; Pileri, A; Ruggieri, D; Tarella, C | 1 |
| Falk, M; Fridrik, MA; Haidinger, R; Hausmaninger, H; Klocker, J; Linkesch, W; Neubauer, M; Pont, J; Radaszkiewicz, T; Raudaschl, G; Schiller, L; Seewann, HL; Sill, H; Stöger, M | 1 |
| Cheng, AL | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Yau, J; Younes, A | 1 |
| Haggag, M; Rodriguez, JM | 1 |
| Avanzini, P; Carotenuto, M; Cavanna, L; Federico, M; Frassoldati, A; Gobbi, PG; Lombardo, M; Pieresca, C; Silingardi, V; Vallisa, D | 1 |
| Ben-Arieh, Y; Ben-Shahar, M; Epelbaum, R; Freidin, N; Haim, N; Leviov, M; Reshef, R | 1 |
| Baker, M; Goss, P; Scott, JG; Shepherd, F; Sutcliffe, S; Sutton, D | 1 |
| Burkes, R; Chow, W; Crump, M; Davidson, M; Goss, P; King, M; Myers, R; Poldre, P; Rudinskas, L; Sutton, D | 1 |
| Dobbs, HJ; Lakhani, A; Mijovic, A; Mufti, GJ; Nethersell, A; Pettingale, KW; Samaratunga, IR; Singer, JM | 1 |
| Fuzimoto, N; Higuchi, M; Itaya, T; Kawamura, M; Maekawa, I; Morioka, M; Nishi, K; Ohmura, T; Okabe, M; Suzuki, S | 1 |
| Haynes, FA; Holcenberg, J; Mayernik, DG; Neidhart, JA; Nemunaitis, J; Oette, DH; Quick, DP; Triozzi, P; Verma, S; Yau, JC | 1 |
| Bower, M; Brock, C; Gulliford, T; Newlands, ES; O'Reilly, SM; Smith, DB | 1 |
| Brandwein, J; Carstairs, K; Colwill, R; Crump, M; Girouard, C; Imrie, K; Keating, A; Pantalony, D; Prince, HM; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM; Tsang, RW | 1 |
| Adde, MA; Arndt, C; Gootenberg, J; Horak, ID; Magrath, IT; Neely, JE; Nieder, ML; Seibel, NL; Shad, AT; Venzon, DJ; Weintraub, M | 1 |
| Adde, M; Arndt, C; Gootenberg, J; Horak, ID; Jaffe, E; Magrath, I; Neely, J; Nieder, M; Seibel, N; Shad, A; Venzon, D; Wittes, RA | 1 |
| Blume, KG; Chao, NJ; Hoyle, CF; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR | 1 |
| Bastit, D; Boulet, D; Fruchart, C; Moncondult, M; Piguet, H; Stamatoullas, A; Tilly, H | 1 |
| Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J | 1 |
| Calabresi, F; De Sanctis, V; Fiacchini, M; Gherlinzoni, F; Mandelli, F; Martelli, M; Martelli, MF; Meloni, G; Papa, G; Tura, S; Vignetti, M; Zinzani, PL | 1 |
| Crowther, D; Deakin, DP; Harris, M; Morgenstern, GR; Pettengell, R; Radford, JA; Ryder, D; Scarffe, JH; Wilkinson, PM; Woll, PJ | 1 |
| Enblad, G; Glimelius, B; Hagberg, H | 1 |
| Bijnens, L; De Wolf-Peeters, C; Hagenbeek, A; Meerwaldt, JH; Noordijk, EM; Pittaluga, S; Somers, R; Teodorovic, I; Thomas, J | 1 |
| Döhner, H; Flentje, M; Goldschmidt, H; Haas, R; Hunstein, W; Möhle, R; Moos, M; Murea, S; Wannenmacher, M; Witt, B | 1 |
| Errante, D; Gastaldi, R; Magnani, G; Nigra, E; Nosari, AM; Spina, M; Tirelli, U; Vaccher, E | 1 |
| Anderson, J; Cassileth, P; Glick, J; Gordon, LI; Habermann, TM; Schilder, RJ; Winter, JN | 1 |
| DeAngelis, LM; O'Brien, JP; Portlock, CS; Wong, ET | 1 |
| Bergmann, L; Hoelzer, D; Karakas, T; Knuth, A; Lautenschläger, G; Mitrou, PS | 1 |
| Anderson, NR; Lokich, JJ; Moore, CL | 1 |
| Vose, JM | 1 |
| Niitsu, N; Umeda, M | 3 |
| Anderson, L; Cunningham, DC; Gregory, WM; Hancock, BW; Hoskin, PJ; Linch, DC; MacLennan, KA; Milligan, DW; Newland, AC; Stevenson, PA; Vaughan Hudson, B; Vaughan Hudson, G; Wood, JK | 1 |
| Bergmann, L; Hoelzer, D; Jager, E; Karakas, T; Knuth, A; Lautenschlager, G; Mitrou, PS | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Buelli, M; Comotti, B; Cortelazzo, S; Fracassetti, D; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Fisher, RI; Gaynor, ER | 2 |
| Okamoto, S; Tanosaki, R | 1 |
| Alvarez, M; Bates, SE; Chabner, B; Fojo, AT; Hose, C; Kang, YK; Monks, A; Regis, J; Robey, R; Wilson, WH; Zhan, Z | 1 |
| Hasegawa, S; Inoue, T; Ishibashi, M; Ishida, M; Katoh, M; Koike, M; Maeba, T; Ohwada, S; Sano, F; Takahashi, M; Tuji, K | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Di Lollo, S; Ferrini, PR; Fusco, II; Innocenti, F; Longo, G; Rigacci, L; Stefanacci, S | 1 |
| Bertini, M; Botto, B; Cinieri, S; Ciotti, R; Di Nota, A; Di Vito, F; Freilone, R; Levis, A; Orsucci, L; Pini, M; Resegotti, L; Rota-Scalabrini, D; Todeschini, G; Vitolo, U | 1 |
| Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC | 1 |
| Andersen, J; Bauer, KD; Fisher, RI; Gordon, LI; Jiang, S; Neiman, RS; Oken, MM; Variakojis, D; Winter, JN | 1 |
| Dutcher, JP; Henry, DH; Hu, X; Mason, B; Ratech, H; Sarta, C; Schwartz, EL; Soeiro, R; Sparano, JA; Wiernik, PH | 1 |
| Ariyoshi, Y; Furue, H; Horiuchi, A; Kagami, Y; Kanamaru, A; Kano, Y; Masaoka, T; Naoe, T; Oguro, M; Ohno, R; Sampi, K; Shirakawa, S | 1 |
| Ashihara, E; Fujita, N; Goto, H; Hatta, T; Hirai, H; Inaba, T; Kikuta, T; Nakagawa, M; Shimazaki, C; Sudo, Y; Sumikuma, T; Yamagata, N | 1 |
| Masaoka, T | 1 |
| Falkson, CI; Nel, JS | 1 |
| Alcalá, A; Bladé, J; Estapé, J; Faura, MV; Fontanillas, M; García-Conde, J; Hernández-Nieto, L; Llorente, A; López-Guillermo, A; Maldonado, J; Montserrat, E; Viñolas, N; Zubizarreta, A | 1 |
| Ben Othman, T; Binet, JL; Fardeau, C; Gerber, S; Leblond, V; Lehoang, P; Merle-Béral, H; Reux, I; Soussain, C; Sutton, L | 1 |
| Juliusson, G; Liliemark, J | 1 |
| Rodriguez, MA | 1 |
| Hanau, L; Henry, DH; Hu, X; Reddy, DM; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Bergmann, L; Hoelzer, D; Jäger, E; Karakas, T; Knuth, A; Mitrou, PS; Stutte, HJ; Weidmann, E | 1 |
| Ezoe, A; Kohda, K; Kuga, T; Matsumoto, S; Mochizuki, C; Nakazawa, O; Niitsu, Y; Nobuoka, A; Watanabe, N | 1 |
| Avalos, BR; Bechtel, TP; Ceselski, SK; Copelan, EA; Elder, PJ; Ezzone, SA; Hehmeyer, DM; Klein, JL; Lasky, LC; Marshall, DD; Penza, SL; Risley, GL; Scholl, MD | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Comotti, B; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Amigo, ML; Caballero, MD; del Cañizo, C; García, R; Gonzalez, M; Hernández, JM; San Miguel, JF; Vazquez, L | 1 |
| Avanzini, P; Baldini, L; Cavanna, L; Colombi, M; Federico, M; Gobbi, P; Guffanti, A; Maiolo, AT; Pieresca, C; Silingardi, V | 1 |
| Baltes-Engler, S; Dederichs, B; Diehl, V; Engelhard, M; Engert, A; Küpper, F; Lathan, B; Reiser, M; Scheulen, ME; Schnell, R; Tesch, H; Wilhelm, M; Winterhalter, B; Wörmann, B | 1 |
| Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M | 1 |
| Havemann, K; Kaiser, U; Pfab, R | 1 |
| Bayer, RA; Broun, ER; Brown, SL; Costa, JJ; Gabrilove, J; Gordon, MS; Hill, J; Ho, AD; Jelaca-Maxwell, K; McNiece, I; Moskowitz, CH; Nichols, CR; Nimer, SD; Stiff, P; Wyres, M | 1 |
| Capochiani, E; Caracciolo, F; Papineschi, F; Petrini, M | 1 |
| Betts, E; Goebel, ME; Honegger, H; Jost, LM; Nagler, A; Stahel, RA | 1 |
| Aitini, E; Bendandi, M; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Leone, G; Liso, V; Magagnoli, M; Moretti, L; Pavone, E; Storti, S; Tabanelli, M; Tura, S; Venturi, S; Zinzani, PL | 1 |
| Ballestrero, A; Brema, F; Ferrando, F; Patrone, F; Puglisi, M; Stura, P | 1 |
| Ascensao, JL; Fontelonga, A; Hall, S; Kelly, AJ; MacKintosh, FR; Monroe, P; Ruthven, A; Shaft, D; Wilson, GS | 1 |
| Adachi, M; Aoki, S; Hayashi, T; Hinoda, Y; Imai, K; Kobayashi, T; Mihara, M; Mori, M; Shimizu, H; Takahashi, T; Tsujisaki, M; Tsukuda, H | 1 |
| Engelhardt, M; Henschler, R; Lange, W; Mertelsmann, R; Waller, C; Winkler, J | 1 |
| Bernengo, MG; Doveil, GC; Fierro, MT; Quaglino, P; Savoia, P; Verrone, A | 1 |
| Bartels, H; Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Nakayama, M; Niitsu, N; Umeda, M | 1 |
| Basser, R; Fox, R; Goss, G; Grigg, A; Szer, J | 1 |
| Bayle, C; Corti, C; Cosset, JM; Girinsky, T; Hayat, M; Nasr, F; Ribrag, V; Rougier, P; Theodore, C | 1 |
| Brandwein, J; Crump, M; Dufresne, J; Girouard, C; Imrie, K; Keating, A; Pantolony, D; Prince, HM; Stewart, AK | 1 |
| Berger, F; Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Felman, P; Ketterer, N; Moullet, I; Neidhardt-Berard, EM; Salles, G | 1 |
| Angus, B; Cameron, DA; Cook, MK; Dawes, PJ; Dawson, AA; Evans, RG; Galloway, MJ; Harris, AL; Heppleston, A; Horne, CH; Krajewski, AS; Lennard, AL; Leonard, RC; Lessells, AM; Lucraft, HH; MacGillivray, JB; Mackie, MJ; Parker, AC; Prescott, RJ; Proctor, SJ; Roberts, JT; Taylor, PR; Thompson, WD; White, JM | 1 |
| Hallahan, D; Mundt, AJ; Williams, SF | 1 |
| Cabanillas, F; Rodriguez-Monge, EJ | 1 |
| Akan, H; Arat, M; Arslan, O; Aydoğdu, I; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Bondesan, P; Caracciolo, D; Castellino, C; Cherasco, C; Corradini, P; Gavarotti, P; Giaretta, F; Pileri, A; Tarella, C | 1 |
| Cassileth, P; Cooper, BW; Fernandez, H; Kutteh, L; Lazarus, HM; Miller, KB; Morelli, J; Pecora, AL; Roitman, D; Schenkein, DP; Stadtmauer, E | 1 |
| Ben-Shahar, M; Epelbaum, R; Faraggi, D; Haim, N; Leviov, M; Tsuri-Etzioni, A | 1 |
| Feng, F; He, X; Zhou, L | 1 |
| Albera, C; Bèguelin, R; Cacchione, R; Campestri, R; Dragosky, M; Dupont, J; Fernández, J; Garay, G; Nicastro, M; Noviello, V; Nucifora, E; Riveros, D; Schnidrig, P; Triguboff, E | 1 |
| Hoskin, PJ | 1 |
| Akan, H; Aydogdu, I; Beksac, M; Gurman, G; Ilhan, O; Koc, H; Konuk, N; Ozerol, E; Uysal, A | 1 |
| Huhn, D; Kingreen, D; Kirsch, A; Kleiner, S; Schwaner, I; Schwella, N; Siegert, W | 1 |
| Bernstein, SH; Christiansen, N; Devos, A; Eaves, CJ; Ericson, S; Fay, J; Hawkins, K; Herzig, GP; Herzig, R; Kovalsky, M; Lynch, J; Phillips, GL; Rasmussen, H; Reece, D; Stephan, M | 1 |
| Bron, D; Errante, D; Kluin-Nelemans, JC; Noordijk, EM; Rosti, G; Somers, R; Teodorovic, I; Thomas, J; Tirelli, U; Van Glabbeke, M; Zagonel, V | 1 |
| Blume, KG; Dahlberg, S; Fisher, RI; Forman, SJ; Horning, SJ; LeBlanc, M; McCall, AR; Nademanee, AP; Stiff, PJ | 1 |
| Goto, S; Kumagai, K; Nakaseko, C; Sakai, C; Takagi, T | 1 |
| Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B | 1 |
| Camoriano, JK; Habermann, TM; Kurtin, PJ; Schroeder, G; Witzig, TE | 1 |
| Fujii, H; Horiike, S; Iwai, T; Kaneko, H; Kashima, K; Misawa, S; Nakagawa, H; Nakao, M; Nakazawa, N; Ookawara, Y; Sasai, Y; Tamura, A; Taniwaki, M; Tsuda, S; Ueda, Y; Yokota, S | 1 |
| Crowther, D; Dobson, L; Huq, T; Lee, SM; Morgenstern, GR; Pettengell, R; Radford, JA; Ryder, WD; Scarffe, JH | 1 |
| Bernasconi, C; Brusamolino, E; Castagnola, C; Lazzarino, M; Pagnucco, G; Passamonti, F | 1 |
| Cadeo, G; Carosi, G; Casari, S; Donisi, A; Re, A; Rossi, G; Stellini, R | 1 |
| Asai, O; Dobashi, N; Kato, A; Katori, M; Kobayashi, T; Kuraishi, Y; Nagamine, M; Tajima, N; Usui, N; Watanabe, H; Yamazaki, H; Yano, S | 1 |
| Asami, K; Eguchi, H; Hatae, Y; Hirota, T; Iwai, A; Katano, N; Koizumi, S; Kono, Y; Matusita, T; Miyawaki, T; Mugisima, H; Nakayama, M; Nisikawa, K; Osima, K; Sekine, I; Simokawa, T; Suzumiya, J; Tanaka, A; Tsuchiya, T; Tsurusawa, M; Utumi, J; Yamamoto, Y; Yamamura, Y; Yanase, T; Yokota, S | 1 |
| Bairey, O; Blickstein, D; Epstein, O; Gabbay, U; Lahav, J; Prokocimer, M; Shaklai, M; Stark, P | 1 |
| Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB | 1 |
| Inoue, K; Kimura, T; Kishimoto, T; Kubota, T; Matsunashi, T; Miyake, S; Nakagawa, M; Ogawa, H; Oji, Y; Sasaki, K; Soma, T; Sugiyama, H; Tani, Y; Tatekawa, T; Yamagami, T | 1 |
| Henry, DH; Hu, X; Ratech, H; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Buckner, CD; Weaver, CH; Zhen, B | 1 |
| Colomer, R; Gómez, H | 1 |
| Cabanillas, F; Dong, K; Hagemeister, FB; McLaughlin, P; Moon, T; Rodriguez, MA; Rodriguez-Diaz Pavón, J; Romaguera, JE | 1 |
| Alcalá, A; Alvarez-Carmona, AM; Besses, C; Carbonell, F; Contreras, E; Fontanillas, M; García-Conde, J; Hernando, A; León, P; López-Guillermo, A; Maldonado, J; Montserrat, E; Sancho-Tello, R; Zubizarreta, A | 1 |
| D'Arco, A; De Renzo, A; Notaro, R; Pagnini, D; Pettinato, G; Pezzullo, L; Rotoli, B | 1 |
| de Wit, M; Erttmann, R; Hänel, M; Hoffknecht, M; Kabisch, H; Kröger, N; Krüger, W; Stockschläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
| Bulabois, CE; Colombat, P; Dupas, B; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, A; Moreau, P; Rapp, MJ; Voillat, L | 1 |
| Bailey, NP; Barnard, DL; Bessell, EM; Child, JA; Cullen, MH; Dunn, J; Farish, J; Fletcher, J; Grieve, RJ; Jack, A; Norfolk, D; Simmons, AV; Stack, C; Stuart, NS; Woodroffe, CM | 1 |
| Bloor, AJ; Marcus, RE; Seale, JR | 1 |
| Gulati, SC; Jhanwar-Uniyal, M | 1 |
| Arai, T; Katano, H; Kumakawa, T; Mori, M; Mori, S; Okada, T; Sawabe, M; Tsutsumi, H | 1 |
| Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P | 1 |
| Centurioni, R; Chisesi, T; Congiu, AM; Contu, A; De Souza, C; Guarnaccia, C; Leoni, P; Majolino, I; Mangoni, L; Nati, S; Olivieri, A; Pescosta, N; Porcellini, A; Rizzoli, V; Rossi, E; Rubagotti, A; Salvagno, L; Santini, G; Sertoli, MR; Soracco, M; Spriano, M; Tedeschi, L; Vespignani, M; Vimercati, R; Zambaldi, G | 1 |
| Aruga, T; Hara, R; Isobe, K; Itami, J; Ito, H; Kimura, S; Kuyama, J; Machida, N; Motoori, K; Uchida, Y; Yamamoto, S; Yasuda, S | 1 |
| Barişta, I; Celik, I; Firat, D; Güler, N; Hayran, M; Kars, A; Ozyilkan, O; Tekuzman, G | 1 |
| Bando, K; Hasegawa, Y; Ohyama, S; Shirayma, H; Taniguti, M | 1 |
| Abboudi, Z; Abrahamson, G; Apperley, JF; Chilcott, S; Craddock, C; Davis, J; Kanfer, EJ; MacDonald, C; Macdonald, D; McGuigan, D; Newlands, ES; Olavarria, E; Philpott, N; Rustin, GJ; Samson, D; Seckl, MJ; Sekhar, M; Stern, S | 1 |
| Igarashi, T; Kobayashi, Y; Murayama, T; Ohtsu, T; Sasaki, Y; Tobinai, K | 1 |
| Hoshino, T; Iwamoto, T; Kuroko, K; Nishida, S; Shirai, C | 1 |
| Ben-Bassat, I; Chetrit, A; Dreiher, J; Raamami, P; Raanani, P; Shpilberg, O | 1 |
| Bachelot, T; Biron, P; Blay, J; Chauvin, F; Gomez, F; Guglielmi, C; Hagenbeek, A; Philip, T; Sebban, C; Somers, R | 1 |
| Bernstein, SH; Christiansen, NP; Fay, JP; Herzig, GP; Pinero, L; Shah, D; Stephan, M | 1 |
| Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Ozyilkan, O; Tekuzman, G; Yalçin, S | 1 |
| Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D | 1 |
| Bigazzi, C; Bocchia, M; Forconi, F; Lauria, F; Marotta, G | 1 |
| Hirayama, A; Kadota, T; Maeda, N; Nakagawa, H; Tsuzuki, T; Yamamoto, H | 1 |
| Bernell, P; Björkholm, M; Celsing, F; Grimfors, G; Hedlund, A; Liliemark, J; Merk, K; Osby, E; Svedmyr, E; Widell, S | 1 |
| Anami, K; Asami, K; Chin, M; Fujimoto, T; Hatae, Y; Hirota, T; Horikoshi, Y; Ito, M; Iwai, A; Kaneko, Y; Katano, N; Kataoka, S; Kikuchi, M; Koizumi, S; Miyawaki, T; Mugisima, H; Nakayama, M; Nishikawa, K; Osima, K; Suzumiya, J; Taga, T; Tanaka, A; Tsurusawa, M; Watanabe, A; Yanase, T | 1 |
| Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B | 1 |
| Dobashi, N; Kuraishi, Y; Usui, N | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Minami, H; Ohtsu, T; Sasaki, Y; Wakita, H; Watanabe, Y | 1 |
| Bogusławska-Jaworska, J; Gorczyńska, E; Słociak, M; Toporski, J | 1 |
| DeVore, RF; Higa, GM; Sarkar, MA | 1 |
| Armand, JP; Couteau, C | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Harris, MB; Krischer, JP; Kung, FH | 1 |
| Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tung, SL; Wang, WS; Yen, CC | 1 |
| Bamborschke, S; Diehl, V; Feiden, W; Lehrke, R; Re, D; Schröder, R; Tesch, H | 1 |
| Cabanillas, F; Fayad, L; Hagemeister, FB; Hess, M; McLaughlin, P; Rodriguez, J; Rodriguez, MA; Romaguera, J; Santiago, M | 1 |
| Economopoulos, T; Fountzilas, G; Pavlidis, N; Raptis, S; Samantas, E; Xiros, N | 1 |
| Buonaiuto, MR; De Renzo, A; Luciano, L; Notaro, R; Pane, F; Rotoli, B; Santoro, LF | 1 |
| Bertino, JR; Elkin, N; Glassman, JR; Moskowitz, CH; Nimer, SD; O'Brien, JP; Portlock, CS; Straus, DJ; Yahalom, J; Zelenetz, AD | 1 |
| Dias Wickramanayake, P; Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Scheid, C; Tesch, H; Wolf, J | 1 |
| Amano, I; Gohda, T; Morii, T; Nakano, H; Narita, N; Nishikawa, K; Shimoyama, T; Tsukaguchi, N; Yagi, H | 1 |
| Barnett, M; Connors, JM; Gascoyne, RD; Horsman, D; Klasa, R; Lesack, D; Macpherson, N | 1 |
| Albin, N; Binet, JL; Boccaccio, C; Charlotte, F; Delort, J; Gabarre, J; Leblond, V; Merle-Béral, H; Souleau, B; Soussain, C; Sutton, L; Zouabi, H | 1 |
| Boqué, C; Cancelas, JA; Garcia, J; Grañena, A; Muñoz, J; Petit, J; Sarrà, J | 1 |
| Brocchieri, A; Grignani, G; Maiolo, A; Merlo, EM; Tua, A | 1 |
| Aitini, E; Bendandi, M; Bocchia, M; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Leone, G; Magagnoli, M; Mazza, P; Moretti, L; Pavone, E; Storti, S; Tabanelli, M; Tura, S; Volpe, E; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Kiss, I; Tomasek, J | 1 |
| Boente, P; Costa, LJ; del Giglio, A; Luzzi, JR; Mota, A; Neves, P; Pinczowski, H; Sampaio, C; Varella, PC | 1 |
| Berkman, E; Hurley, C; Kanteti, R; McCann, J; Miller, K; Morelli, J; Roitman, D; Schenkein, D | 1 |
| Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S | 1 |
| Byrne, J; Haynes, A; McQuaker, I; Russell, N; Stainer, C | 1 |
| Baccarani, M; Cerno, M; Damiani, D; Fanin, R; Geromin, A; Grimaz, S; Infanti, L; Michieli, M; Savignano, C; Silvestri, F; Skert, C; Sperotto, A | 1 |
| Chott, A; Ebell, W; Graf, N; Henze, G; Klingebiel, T; Kremens, B; Ludwig, WD; Mann, G; Müller-Weihrich, S; Plüss, HJ; Reiter, A; Riehm, H; Schrappe, M; Tiemann, M; Yakisan, E; Zimmermann, M; Zintl, F | 1 |
| Cassileth, PA; Flynn, P; Ghosh, C; Glick, J; Gordon, LI; Habermann, TM; Weller, E; Winter, JN; Young, M | 1 |
| Keyaki, A; Nabeshima, S; Waga, S | 1 |
| Agus, DB; Bertino, JR; Childs, B; Coady-Lyons, N; Filippa, D; Frank, R; Glassman, JR; Goy, A; Hedrick, EE; Hunte, S; Jurcic, J; Louie, D; Moskowitz, CH; Nimer, SD; Noy, A; O'Brien, J; Portlock, CS; Straus, DS; Yahalom, J; Zelenetz, AD | 1 |
| Abate, G; Bianco, AR; Catalano, G; D'Aprile, M; Dammacco, F; De Lena, M; De Vita, F; Lauta, VM; Lorusso, V; Lucarelli, G; Mantovani, G; Marzullo, F; Palmieri, G; Polimeno, G | 1 |
| Ali, NM; Darwish, T; Elattar, I; Gaafar, R; Khaled, HM; Moawad, MS; Mokhtar, N; Zekri, ZK | 1 |
| al-Rawithi, S; Berry, J; el-Yazigi, A; Ezzat, A; Legayada, ES; Raines, DA; Yusuf, A | 1 |
| Brandt, SJ; Goodman, S; Greer, JP; Macon, WR; McCurley, TL; Morgan, DS; Stein, RS; Wolff, SN | 1 |
| Chihara, K; Inoue, R; Iwata, N; Kajimoto, Y; Matsui, T; Matsuoka, H; Natazuka, T; Shimoyama, M; Tamekane, A | 1 |
| Chisesi, T; Congiu, AM; Contu, A; Coser, P; De Souza, C; Marino, G; Nati, S; Olivieri, A; Porcellini, A; Rizzoli, V; Rubagotti, A; Salvagno, L; Santini, G; Sertoli, MR; Truini, M; Zambaldi, G | 1 |
| Ascari, E; Avanzini, P; Baldini, L; Broglia, C; Ghirardelli, ML; Gobbi, PG; Loni, C; Quarta, G; Silingardi, V; Stelitano, C | 1 |
| Anderlini, P; Andersson, B; Blamble, DA; Cabanillas, F; Champlin, RE; Donato, ML; Durett, A; Gajewski, JG; Gee, A; Giralt, S; Hagemeister, F; Hester, J; Ippoliti, C; Khouri, I; Korbling, M; Lauppe, J; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Sarris, A; Van Besien, KW; Younes, A | 1 |
| Cavenagh, JD; Eden, AG; Hughes, A; Kelsey, SM; Lamont, A; McBride, NC; Mills, MJ; Newland, AC; Ward, MC | 1 |
| Cunningham, DC; Gregory, WM; Hancock, BW; Hoskin, PJ; Linch, DC; Maclennan, KA; Milligan, D; Newland, AC; Smith, P; Stevenson, PA; Vaughan, B; Vaughan, G; Wood, JK | 1 |
| Bourhis, JH; Brault, P; Fenaux, P; Koscielny, S; Munck, JN; Pico, J; Ribrag, V; Vantelon, JM | 1 |
| Dive, C; Hickman, JA; Taylor, ST | 1 |
| Barnett, MJ; Connors, JM; Gascoyne, RD; Hogge, DE; Klingemann, HG; Nantel, SH; Nevill, TJ; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ; Toze, CL; Voss, NJ | 1 |
| Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F | 1 |
| Devine, S; Heffner, LT; Jones, TW; Lonial, S; Smith, KJ; Waller, EK; Winton, EF; Yeager, AM | 1 |
| Balcerzak, SP; Dana, BW; Fisher, RI; Forman, JD; Gaynor, ER; Kjeldsberg, C; LeBlanc, M; Miller, T; Roy, V; Unger, JM | 1 |
| Buthmann, U; Freund, M; Kleine, HD; Volk, J | 1 |
| Ayala-Sánchez, M; Esparza, MA; García-León, LD; González-Llaven, J; Guevara-Moreno, ME; Montiel-Cervantes, L; Rosas-Cabral, A; Sánchez-Cortés, E; Tripp-Villanueva, F; Vela-Ojeda, J | 1 |
| Andresen, SW; Avalos, BR; Bechtel, TP; Bolwell, BJ; Copelan, EA; Elder, PJ; Ezzone, SA; Goormastic, M; Kalaycio, M; O'Donnell, LC; Penza, SL; Pohlman, B; Risley, GL; Scholl, MD; Tighe, MB; Young, DC | 1 |
| Alvarnas, JC; Blume, KG; Chao, NJ; Horning, SJ; Hu, WW; Long, GD; Negrin, RS; Schriber, JR; Stockerl-Goldstein, K; Tierney, K; Wong, R | 1 |
| Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H | 1 |
| Chen, J; Wang, Z | 1 |
| Luo, Y; Wang, A; Wang, Z | 1 |
| Aboud, W; Berkelhammer, C; Marshall, R | 1 |
| Barbarano, L; Bernuzzi, P; Gargantini, L; Morra, E; Nosari, A; Pungolino, E; Santoleri, L | 1 |
| Cowan, RA; Deakin, DP; Harris, M; Radford, JA; Wilkinson, PM; Wylie, JP | 1 |
| Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M | 1 |
| Bosly, A; Brice, P; Brière, J; Coiffier, B; Gaulard, P; Gisselbrecht, C; Haioun, C; Lederlin, P; Lepage, E; Morel, P; Nouvel, C; Reyes, F; Salles, G; Sebban, C; Tilly, H | 1 |
| Cazals-Hatem, D; Chevret, S; Clauvel, JP; Dubreuil, ML; Gerard, L; Levy, Y; Matheron, S; Oksenhendler, E | 1 |
| Cabanillas, F | 3 |
| Giebel, S; Hołowiecki, J; Kachel, L; Kata, D; Krawczyk-Kuliś, M; Markiewicz, M; Wojciechowska, M; Wojnar, J | 1 |
| Donnelly, GB; Hedrick, EE; Hunte, S; Kewalramani, T; Lyons, NC; Moskowitz, CH; Nimer, SD; Priovolos, AC; Qin, J; Yahalom, J; Zelenetz, AD | 1 |
| Hirano, M; Kodama, F; Kuraishi, Y; Nakamura, S; Niitsu, N; Okamoto, M | 1 |
| Andrews, DF; Gilmore, GL; Lister, J; Shadduck, RK; Zeigler, ZR | 1 |
| Aoyama, Y; Hino, M; Kamitani, T; Kishida, T; Koh, KR; Mugitani, A; Nakamae, H; Ohta, K; Ota, T; Sannomiya, Y; Takubo, T; Tatsumi, N; Yamane, T | 1 |
| Ashihara, E; Hatsuse, M; Inaba, T; Nakagawa, M; Okano, A; Shimazaki, C | 1 |
| Ballestrero, A; Clavio, M; Ferrando, F; Garuti, A; Ghio, R; Gobbi, M; Gonella, R; Patrone, F; Sessarego, M | 1 |
| Lei, Y; Shi, Y; Zhou, S | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Chabner, BA; Cheson, BD; Fojo, A; Gutierrez, M; Jaffe, ES; Pearson, D; Steinberg, SM; Wilson, WH | 1 |
| Barcos, M; Carlisle, TL; Cooper, MR; Johnson, JL; Lichtman, SM; Niedzwiecki, D; Peterson, BA | 1 |
| Blume, KG; Chao, NF; Feiner, RH; Horning, SF; Hu, WW; Johnston, LF; Kobler, S; Long, GD; Negrin, RS; Reddy, SA; Stockerl-Goldstein, KE; Strober, S; Wong, RM | 1 |
| Blume, KG; Hoppe, RT; Horning, SJ; Hu, WW; Johnston, LJ; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Blaise, D; Caraux, J; Chabannon, C; Faucher, C; Maraninchi, D; Vey, N | 1 |
| Ambrosetti, A; Corato, A; de Wynter, E; Lambiase, A; Nadali, G; Perona, G; Pizzolo, G; Rossi, B; Vincenzi, C | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Fujimori, Y; Itoh, T; Kakishita, E; Mori, A; Nishimura, Y; Okada, M; Okamoto, T; Saheki, K; Takatsuka, H; Tamura, A; Wada, H; Yamada, S | 1 |
| Achour, E; Azar, N; Belanger, C; Cassoux, N; Delattre, JY; Gerber, S; Hoang-Xuan, K; Leblond, V; Levy, V; Ribrag, V; Soussain, C; Suzan, F | 1 |
| Fenstad, GU; Skovlund, E | 1 |
| Ahmed, T; Durrani, H; Kancherla, RR; Mannancheril, A; Nair, JS; Seiter, K; Tse-Dinh, YC | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Alscher, A; Casper, J; Decker, S; Freund, M; Junghanss, C; Kleine, HD; Knopp, A; Köhne, CH; Leithäuser, M; Wilhelm, S | 1 |
| Azzarà, A; Capochiani, E; Carulli, G; Petrini, M; Rizzuti-Gullaci, A | 1 |
| Gutierrez, M; Horne, M; Jaffe, ES; Little, RF; Pau, A; Wilson, W | 1 |
| Anderson, JR; Cohen, MD; DeLaat, C; Gilchrist, GS; Kobrinsky, NL; Meadows, AT; Morse, M; Shah, NR; Shina, D; Sposto, R; Warkentin, P | 1 |
| Chisesi, T; Congiu, AM; Contu, A; Coser, P; Indrizzi, L; Leoni, P; Majolino, I; Polistena, P; Porcellini, A; Rizzoli, V; Salvagno, L; Santini, G; Zambaldi, G | 1 |
| Cunningham, D; Gregory, W; Hancock, B; Hoskin, P; Hudson, GV; Linch, D; MacLennan, K; Mainwaring, PN; Norton, AJ; Smith, P | 1 |
| Arima, N; Doi, S; Fujimoto, M; Fukuhara, S; Hayashi, K; Katsurada, T; Kitajima, H; Konaka, Y; Moriguchi, T; Nasu, K; Ohno, H; Tsudo, M | 1 |
| Cabanillas, FF; Cox, JD; Ha, CS; Hess, MA; Rodriguez, MA; Tucker, SL; Wilder, RB | 1 |
| Gentile, TC; Haider, K; Mathur, S; Schachtner, JM; Smith, AL; Vanorden, R | 1 |
| Fletcher, BD; Harrison, PL; Kaste, SC; Kennedy, W; Neel, MD; Pui, CH; Razzouk, BI; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT | 1 |
| Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C | 1 |
| Cartron, G; Colombat, P; De Muret, A; Desablens, B; Dugay, J; Foussard, C; Le Maignan, C; Maakaroun, A; Milpied, N; Voillat, L | 1 |
| Antinori, A; Fasan, M; Juzbasic, S; Milan, I; Nasti, G; Nigra, E; Spina, M; Talamini, R; Tirelli, U; Vaccher, E | 1 |
| Flynn, PM; Harrison, PL; Hughes, W; Relling, MV; Schuetz, EG; van de Poll, ME | 1 |
| Bartlett, NL; Canellos, GP; Gockerman, JP; Johnson, JL; Omura, GA; Parker, BA; Peterson, BA; Petroni, GR; Robert, M; Wagner, ND | 1 |
| Coleman, M; Kaufman, TP; Leonard, J; Shuster, MW | 1 |
| Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ | 1 |
| Barbui, T; Benedetti, F; Cavalli, F; Cortelazzo, S; Di Nicola, M; Ghielmini, M; Gianni, AM; Oldani, E; Pogliani, E; Rambaldi, A; Rossi, A; Tarella, C; Vitolo, U; Zaglio, F | 1 |
| Barcos, M; Bloomfield, CD; Freter, CE; Frizzera, G; Johnson, JL; Lee, EJ; Peterson, BA; Petroni, GR; Schiffer, CA | 1 |
| Assawametha, N; Intragumtornchai, T; Numbenjapon, T; O'Charoen, R; Prayoonwiwat, W; Swasdikul, D | 1 |
| Jain, VK; Ogden, JL; Wilder, DD | 1 |
| D'Orazio, AI | 1 |
| Bi, J; Boswell, W; Espina, BM; Levine, AM; Tulpule, A | 1 |
| Guidos, BJ; Selvaggi, SM | 1 |
| Baudis, M; Bentz, M; Döhner, H; Fritz, B; Kloess, M; Lichter, P; Schwänen, C; Walenta, K; Wessendorf, S | 1 |
| Klöss, M; Loeffler, M; Nguyen, TP; Pfreunschuh, M; Rübe, C; Trümper, L | 1 |
| Blume, KG; Chao, NS; Horning, SJ; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Kakishita, E; Mori, A; Okada, M; Okamoto, T; Takatsuka, H; Wakae, T | 1 |
| Birkmann, J; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Hoffknecht, MM; Kröger, N; Kroschinsky, F; Krüger, W; Metzner, B; Schmid, B; Sonnenberg, S; Zander, AR | 1 |
| Bordessoule, D; Bosly, A; Coiffier, B; Deconninck, E; Divine, M; Dupriez, B; Fillet, G; Gaulard, P; Gisselbrecht, C; Herbrecht, R; Lepage, E; Nouvel, C; Tilly, H | 1 |
| Armitage, JO; Bierman, PJ; Chan, WC; Inwards, D; Kessinger, A; Loh, K; Lynch, JC; Nichols, C; Rifkin, R; Sharp, G; Vose, JM; Weisenburger, DD | 1 |
| Moskowitz, C | 1 |
| Antoniolli, SZ; Curti, P; D'Amico, A; Ficarra, V; Malossini, G; Martignoni, G; Matteo, B; Novella, G; Porcaro, AB | 1 |
| Bergman, S; Creager, AJ; Geisinger, KR | 1 |
| Amiel, JL; Hayat, M; Mathé, G; Pouillart, P; Schwarzenberg, L; Tubiana, M | 1 |
| Dommann, C; Gebbers, JO; Honegger, HP; Joss, R; Kroner, T; Maurer, R; Peters, J; Pichert, G; Stahel, RA; Sulser, H | 1 |
| Bianconcini, G; Candini, R; Dallasta, A; Gobbi, F; Mazzali, F | 1 |
| Bar-Ziv, J; Gilon, D; Polliack, A; Putterman, C; Uretzki, G | 1 |
| Aversa, SM; Bianco, A; Chiarion-Sileni, V; Contu, A; Endrizzi, L; Fiorentino, MV; Olmeo, N; Salvagno, L; Schintu, GM; Sorarù, M | 1 |
| Gibson, J; Joshua, DE; Kronenberg, H; Mansberg, R | 1 |
| Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X | 1 |
| Ezaki, K; Hirano, M; Ino, T; Maruyama, F; Matsui, T; Miyazaki, H; Okamoto, M; Shimizu, K; Shinkai, K; Sobue, R | 1 |
| Cerrillo, M; Cervantes, G; Gagnière, M; Gorodezky, G; Mohar, A; Neyra, O; Osornio, A; Reynoso, E; Salles, MT; Taja, L | 1 |
| Arnold, H; Bross, K; Heidemann, E; Heim, ME; Hoffman, I; Josten, K; Manegold, C; Reinold, HM; Schalk, KP; Steinke, B | 1 |
| de Campos, E; Demuynck, H; Dexter, TM; Pettengell, R; Testa, NG | 1 |
| Mizoguchi, H; Saito, H | 1 |
| Bentley, J; Crowther, D; Deakin, DP; Gurney, H; James, R; Kane, K; Pettengell, R; Radford, JA; Wilkinson, PM | 1 |
| Bishop, PW; Crowther, D; Pettengell, R | 1 |
| Bergerat, JP; Damonte, JC; Dufour, P; Herbrecht, R; Liu, KL; Maloisel, F; Oberling, F; Ortiz, S | 1 |
| Chisa, M; Hasegawa, S; Katoh, M; Koike, M; Kubomatsu, Y; Kunika, N; Nakamura, K; Sano, F; Takahashi, M; Wakayama, T | 1 |
| Greco, FA; Hainsworth, JD; Johnson, DH | 2 |
| Young, RC | 1 |
| Horiuti, A; Kakishita, E; Kanamaru, A; Masaoka, T; Miyazaki, E; Nagai, K; Shibata, H; Takemoto, Y; Tsubaki, K; Yonezawa, T | 1 |
| Acaba, L; Crown, J; Gulati, S; Hanninen, E; Igarashi, T; Lemoli, R; Motzer, R; Reich, L; Toia, M; Yahalom, J | 1 |
| Oguro, M; Sakai, C; Takagi, T | 1 |
| Ben-Shahar, M; Epelbaum, R; Haim, N; Robinson, E; Rosenblatt, E; Wollner, M | 1 |
| Armitage, JO; Bierman, PJ; Glenn, LD; Kessinger, A; Reed, EC; Vaughan, WP | 1 |
| Douay, L; Eugene-Jolchine, I; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A; Stachowiak, J | 1 |
| Abate, G; Comella, P; Daponte, A; Di Finizio, G; Zarrilli, D | 1 |
| Dent, DM; Jacobs, P; King, HS | 1 |
| Dahlberg, S; Eyre, HJ; Files, JC; Fisher, RI; Miller, TP; Pendergrass, KB; Weick, JK | 1 |
| Cossman, J; DeVita, VT; Duffey, PL; Fisher, RI; Gilliom, M; Hubbard, SM; Ihde, DC; Jaffe, ES; Longo, DL; Wesley, MN | 1 |
| Avilés, A; Díaz-Maqueo, JC; López Vancell, D; Rodríguez, L; Torras, V | 1 |
| Andersen, J; Bentzen, SM; Brincker, H; Christensen, BE; Pedersen, M; Thorling, K | 1 |
| Greco, FA; Greer, JP; Hainsworth, JD; Hildreth, CR; Johnson, DH; McMaster, ML; Wolff, SN | 1 |
| DeAngelis, LM; Gnecco, C; Taylor, L; Warrell, RP | 1 |
| Dahlberg, S; Fisher, RI; Miller, TP | 1 |
| Greco, FA; Greer, JP; Hainsworth, JD; Johnson, DH; McMaster, ML; Wolff, SN | 1 |
| Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S | 1 |
| DeVita, VT; Fisher, RI; Hubbard, SM; Longo, DL; Miller, TP; Young, RC | 1 |
| Brack, N; Brittinger, G; Dornoff, W; Engelhard, M; Enne, W; Gassmann, W; Gerhartz, H; Hallek, M; Heise, J; Meusers, P | 1 |
| Cousar, JB; Flexner, JM; Greco, FA; Greer, JP; Hainsworth, JD; Johnson, DH; McMaster, ML; Stein, RS; Wolff, SN | 1 |
| Capnist, G; Chisesi, T; Contu, A; Coser, P; Porcellini, A; Rancan, L; Rizzoli, V; Salvagno, L; Santini, G; Sertoli, M | 1 |
| Abbadessa, V; Avanzini, P; Carotenuto, M; Cavanna, L; Federico, M; Gobbi, PG; Leone, G; Lombardo, M; Moretti, G; Pitini, V | 1 |
| Mead, GM; Sweetenham, JW; Whitehouse, JM | 1 |
| Cao, C; García, H; Gutiérrez, J; Osorio, G; Vacarezza, R | 1 |
| Carbone, A; De Cicco, M; Errante, D; Monfardini, S; Serraino, D; Talamini, R; Tirelli, U; Zagonel, V | 1 |
| Carrión, JR; Delgado, JR; Dominguez, S; Flores, E; Garcia, P; Jaen, J; Santos, JA | 1 |
| Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Peters, C | 1 |
| Baurmann, H; Henze, G; Kleiner, S; Schmid, H; Schwerdtfeger, R; Siegert, W; Zeiler, T | 1 |
| Bron, D; Coiffier, B; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Kluin Nelemans, JC; Misset, JL; Philip, T; Somers, R; Van der Lely, J | 1 |
| Fukuchi, K; Ikeuchi, T; Kodo, H; Mori, S; Sugawara, I; Sugiyama, H; Yoshikai, Y | 1 |
| Connors, JM; Klimo, P; O'Reilly, SE | 1 |
| Björkholm, M; Ideström, K; Johansson, B; Kimby, E; Lindemalm, C; Merk, K; Osby, E | 1 |
| Nielsen, H | 1 |
| Brincker, H; Mirza, MR | 1 |
| Honda, J; Imamura, Y; Naito, K; Nakamura, E; Natori, H; Oizumi, K; Osabe, S; Sakamoto, A; Tanaka, K; Yosida, K | 1 |
| Bloom, EJ; Buck, DS; Przepiorka, D; Rosenfeld, CS; Schwinghammer, TL; Shadduck, RK | 1 |
| Baker, MA; Buick, S; Farquharson, HA; Goss, PE; Scott, JG; Shepherd, FA; Sutcliffe, S; Sutton, D; Warner, E | 1 |
| Blume, KG; Chao, NJ; Hoppe, RT; Horning, SJ; Kwak, LW; Long, GD; Negrin, RS; O'Connor, P; Stallbaum, B | 1 |
| Clarkson, BD; Gee, T; Gulati, SC; Whitmarsh, K; Yahalom, J | 1 |
| Bron, D; Chauvin, F; Coiffier, B; Gisselbrecht, C; Guglielmi, C; Hagenbeek, A; Kluin Nelemans, JC; Misset, JC; Philip, T; Somers, R | 1 |
| Hirano, A; Horikoshi, N; Inoue, K; Matsumura, T; Matsuoka, A; Mizunuma, N; Mukaiyama, T; Ogawa, M | 1 |
| Biron, P; Cahn, JY; Colombat, P; Gorin, NC; Herve, P; Lamagnere, JP; Laporte, JP; Philip, T | 1 |
| Debranin, CO | 1 |
| Bruntsch, U; Eschenbach, I; Gropp, C; Köppler, H; Lötzke, E; Oehl, S; Pfab, R; Pflüger, KH; Steinhauer, EU; Zeller, W | 1 |
| Akard, L; Broun, ER; Cheerva, A; Jansen, J; Nichols, C; Tricot, G | 1 |
| Chao, NJ; Horning, SJ; Rosenberg, SA | 1 |
| Benz-Lemoine, E; Biron, P; Colombat, P; Demeocq, F; Frappaz, D; Harousseau, JL; Lamagnère, JP; Patte, C; Philip, T | 1 |
| Armitage, JO; Maragos, D; Schouten, HC; Vose, J | 1 |
| Carbone, A; Errante, D; Monfardini, S; Morassot, S; Sorio, R; Tirelli, U; Zagonel, V | 1 |
| Antin, JH; Ault, KA; Bubley, GJ; Churchill, WH; Come, SE; Rappaport, JM; Rosenthal, DS; Schnipper, LE; Smith, BR; Wheeler, C | 1 |
| Bergeron, C; Demaille, MC; Gentet, JC; Patte, C; Pein, F; Philip, T; Quintana, E; Raybaud, C; Rubie, H | 1 |
| Fornasier, V; Keystone, EC; Sturgeon, JF; Thomson, GT | 1 |
| Enblad, G; Glimelius, B; Hagberg, H; Lindemalm, C | 1 |
| Brousse, N; Herrera, A; Peuchmaur, M; Solal-Celigny, P; Tertian, G | 1 |
| Coltman, CA; Dahlberg, S; Dana, BW; Fisher, RI; Jones, SE; Miller, TP | 1 |
| Cossman, J; Glatstein, E; Lawrence, TS; Steinberg, SM; Sundeen, JT; Urba, WJ; Young, RC | 1 |
| Brittinger, G; Dörken, B; Engelhard, M; Engert, W; Enne, W; Fuchs, R; Gerhartz, HH; Hagen-Aukamp, CH; Huhn, D; Thiel, E | 1 |
| Brittinger, G; Engelhard, M; Gerhartz, H; Heinz, R; Huhn, D; Meusers, P; Neubauer, A; Siegert, W; Stacher, A; Thiel, E | 1 |
| Arnold, H; Busch, FW; Günther, E; Heim, ME; Kraft, H; Krüger, HU; Steinke, B | 1 |
| DeVita, VT; Glatstein, E; Ihde, DC; Jaffe, ES; Longo, DL; Young, RC | 1 |
| Coltman, CA; Dahlberg, S; Dana, BW; Fisher, RI; Jones, SE; Miller, TP; Weick, JK | 1 |
| Diehl, V; Schaadt, M; von Kalle, AK | 1 |
| Bross, K; Heidemann, E; Heim, ME; Hofmann, I; Josten, K; Kraft, A; Löffler, B; Reinold, HM; Richter, C; Steinke, B | 1 |
| Brittinger, G; Engelhard, M; Gerhartz, HH; Heinz, R; Huhn, D; Meusers, P; Siegert, W; Stacher, A; Thiel, E; Wilmanns, W | 1 |
| Bergerat, JP; Duclos, B; Dufour, P; Garcia, JJ; Herbrecht, R; Oberling, F | 1 |
| Anders, C; Höffken, K; Meier, CR; Nowrousian, MR; Osieka, R; Schmidt, CG; Schoetensack, B | 1 |
| Armitage, JO; Bierman, PJ; Kessinger, A; Landmark, JD; Smith, DM; Weisenburger, DD | 1 |
| Ritch, PS; Schiller, JH; Storer, B; Trump, DL | 1 |
| Kanai, M; Kanno, M; Kobayashi, K; Kondo, K; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Yoshida, T | 1 |
| Kano, Y; Masaoka, T; Mikuni, C; Sakamoto, S; Sampi, K; Takagi, T | 1 |
| Kaplan, LD; Volberding, PA | 1 |
| Eschenbach, I; Gassel, WD; Hässler, R; Kolb, T; Köppler, H; Lennert, K; Pfab, R; Pflüger, KH; Schmidt, M; Wellens, W | 1 |
| Cruz, JM; Jackson, DV; Muss, HB; Powell, BL; Spurr, CL | 1 |
| Bagshawe, KD; Begent, RH; Boesen, E; Glaser, MG; Ledermann, JA; Newlands, ES; Rustin, GJ; Smith, DB | 1 |
| Coe, MA; Errington, RD; Green, JA; Nash, JR; Warenius, HM | 1 |
| Abdel-Hadi, S; Adde, M; el-Taneer, O; Gad-el-Mawla, N; Hussein, MH; Magrath, I | 1 |
| McVie, G; Muggia, FM | 1 |
| Ito, K; Kanamori, K; Kanno, M; Kobayashi, K; Kondo, K; Matsuda, T; Nakamura, S; Nakazumi, Y; Yoshida, T | 1 |
| Grieve, RJ; Harris, RI; Leyland, MJ; Patton, WN; Sangster, G | 1 |
| Glatte, P; Osieka, R; Pannenbäcker, R; Schmidt, CG; Seeber, S; Soll, D | 1 |
| Dabich, L; Liepman, MK | 1 |
| Imura, H; Ino, T; Ito, N; Kojima, H; Maruyama, F; Matsui, T; Shimizu, K; Shinkai, K; Shirakawa, S; Sobue, R | 1 |
| Hirai, J; Itoh, K; Kanno, M; Kobayashi, K; Matsuda, T; Naito, K; Nakamura, E; Nakamura, S; Ohtake, S; Yoshida, T | 1 |
| Allan, NC; Dawson, AA; Leonard, RC; Lucraft, HH; McGillivray, JB; Parker, AC; Prescott, RJ; Proctor, SJ | 1 |
| Eschenbach, I; Gassel, WD; Hässler, R; Kolb, T; Köppler, H; Lennert, K; Loetzke, E; Pfab, R; Pflüger, KH; Schmidt, M | 1 |
| Blume, KG; Forman, SJ | 1 |
| Hirai, J; Itoh, K; Kanno, M; Kobayashi, K; Matsuda, T; Nakamura, S; Ohtake, S; Saito, Y; Tachimori, K; Yoshida, T | 2 |
| Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Kohsaki, M; Masaoka, T; Nagai, K; Shibata, H; Tagawa, S; Tsubaki, K | 1 |
| de Bruïne, FT; Peters, WG; Tham, RT; Willemze, R | 1 |
| Baccarani, M; Bandini, G; Gherlinzoni, F; Lauria, F; Mazza, P; Ricci, P; Rosti, G; Tura, S; Visani, G; Zaccaria, A | 1 |
| Hayashi, K; Kimura, I; Murashima, M; Ohnoshi, T; Tada, A; Ueno, K; Ueoka, H; Yamane, T; Yoshida, M | 2 |
| Atkins, JN; Capizzi, RL; Caponera, ME; Craig, JB; Jackson, DV; Muss, HB; Powell, BL; Richards, F; White, DR; Zekan, PJ | 1 |
| Canetta, R; Carbone, A; Tirelli, U; Veronesi, A; Zagonel, V | 1 |
| Gordon, LI; Hauck, WW; Variakojis, D; Winter, JN | 1 |
| Fahey, JL; Farbstein, MJ; Forman, SJ; Gill, P; Lazar, G; Levine, AM; Nademanee, A; Neely, S; O'Donnell, MR; Territo, M | 1 |
| Horikoshi, N; Imajo, K; Inagaki, J; Inoue, K; Ito, Y; Mukaiyama, T; Nakamura, T; Ogawa, M; Ueno, K; Yamazaki, H | 1 |
50 review(s) available for etoposide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Double-Hit Large B Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mutation; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; Vincristine | 2017 |
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; HIV; HIV Infections; Humans; Infusions, Intravenous; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2013 |
[Malignant lymphoma and adult T-cell leukemia-lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Genetic Markers; Genetic Testing; Hodgkin Disease; Humans; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Methylprednisolone; Positron-Emission Tomography; Prednisone; Vincristine | 2014 |
Rituximab-associated neutropenia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Chemokine CXCL12; Cyclophosphamide; Doxorubicin; Etoposide; Granulocytes; Homeostasis; Humans; Incidence; Lymphoma, Non-Hodgkin; Neutropenia; Prednisone; Rituximab; Time Factors; Vincristine | 2010 |
Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Odds Ratio; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome; Vincristine | 2012 |
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Secondary Prevention; Stem Cell Transplantation | 2003 |
Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Italy; Lymphoma, Non-Hodgkin | 2003 |
[Erythema nodosum association with malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Erythema Induratum; Erythema Nodosum; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paraneoplastic Syndromes; Prednisolone; Prednisone; Pregnancy; Procarbazine; Remission Induction; Vincristine | 2003 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Idarubicin; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Prednisolone; Prednisone; Vincristine | 2003 |
What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Administration Schedule; Etoposide; Forecasting; Humans; Lymphoma, Non-Hodgkin; Mechlorethamine; Multicenter Studies as Topic; Pilot Projects; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2004 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradiation; Cytarabine; Dementia; Dementia, Vascular; Demyelinating Diseases; Disease Progression; Doxorubicin; Epilepsy, Complex Partial; Etoposide; Eye Neoplasms; Fatal Outcome; Female; Gait Disorders, Neurologic; Humans; Immunocompetence; Intracranial Arteriosclerosis; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Procarbazine; Radiation Injuries; Retrospective Studies; Survival Analysis; Thiotepa; Vincristine | 2004 |
Improving second-line therapy in aggressive non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2004 |
Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
Testicular granulocytic sarcoma, a source of diagnostic confusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Cyclophosphamide; Cytarabine; Cytoplasmic Granules; Daunorubicin; Diagnosis, Differential; Diagnostic Errors; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisolone; Sarcoma, Myeloid; Testicular Neoplasms; Vincristine | 2004 |
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Prednisone; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rituximab; RNA, Messenger; Survival Analysis; Thionucleotides; Transplantation, Heterologous; Vincristine | 2004 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
Transverse nail ridgings (Beau's lines) induced by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Head and Neck Neoplasms; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Nail Diseases; Nails; Prednisone; Vincristine | 1994 |
Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Vincristine | 1994 |
[Malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Vincristine | 1994 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Neoplasms; Neuroblastoma; Neutropenia; Sarcoma; Thrombocytopenia; Wilms Tumor | 1995 |
Teniposide: overview of its therapeutic potential in adult cancers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Etoposide; Female; Genital Neoplasms, Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma, Kaposi; Teniposide | 1994 |
Epipodophyllotoxins in the treatment of childhood cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Second Primary; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies | 1994 |
Chronic etoposide administration: overview of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug Administration Schedule; Etoposide; Female; Germinoma; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Ovarian Neoplasms | 1993 |
Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the W
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Immunologic Factors; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Prognosis; Recombinant Proteins; Survival Analysis; Survival Rate; Vincristine | 1996 |
Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Salvage Therapy; Transplantation, Autologous | 1996 |
Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Vincristine | 1995 |
[High-clore chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with malignant lymphoma--its role in the treatment strategy for non-Hodgkin's lymphoma, and ESHAP + PBSCT therapy].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Prednisone; Transplantation, Autologous | 1996 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, Non-Hodgkin; Prednisone; Verapamil; Vincristine | 1996 |
[Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary | 1996 |
[Etoposide 21 therapy for malignant lymphoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Palliative Care | 1996 |
Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Prognosis | 1996 |
[Value of radiotherapy in disseminated high-grade non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Radiation; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Prednisolone; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Vincristine | 1997 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Palliative Care; Prednimustine; Prednisolone; Prednisone; Prognosis; Vincristine | 1998 |
Body-cavity-based lymphoma in an elderly AIDS-unrelated male.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Fatal Outcome; Herpesviridae Infections; Herpesvirus 4, Human; Herpesvirus 8, Human; Humans; Lymphoma, Non-Hodgkin; Male; Pericardial Effusion; Pleural Effusion, Malignant; Tumor Virus Infections | 1998 |
[Chylothorax resulting from malignant non Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chylothorax; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Remission Induction; Vincristine | 1998 |
[Chemotherapy for non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Vincristine | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Encephalitis; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Injections, Spinal; Interferon-alpha; Interleukin-12; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Melphalan; Memory Disorders; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1999 |
Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; CD40 Antigens; Cell Survival; Drug Resistance, Neoplasm; Etoposide; Germinal Center; Humans; Immunoglobulin G; Integrin alpha4beta1; Integrins; Interleukin-4; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mice; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin-4; Receptors, Lymphocyte Homing; Tumor Cells, Cultured; Vascular Cell Adhesion Molecule-1 | 1999 |
Germ cell neoplasms and other malignancies of the mediastinum.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Carcinoma; Child; Cisplatin; Combined Modality Therapy; Etoposide; Genetic Predisposition to Disease; Germinoma; Hematologic Neoplasms; Humans; Incidence; Klinefelter Syndrome; Lymphoma, Non-Hodgkin; Mediastinal Neoplasms; Neoplasm Staging; Neoplasms, Multiple Primary; Neoplasms, Nerve Tissue; Radiotherapy, Adjuvant; Seminoma; Treatment Outcome | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infections; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Survival Analysis; Thrombocytopenia; Vincristine | 2001 |
Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human; Cyclophosphamide; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Life Tables; Lymphoma, Non-Hodgkin; Metaphase; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Prednisolone; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2001 |
Primary lymphoma of the kidney. Report of a case and update of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Immunophenotyping; Kidney; Kidney Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Staging; Nephrectomy; Prednisone; Vincristine | 2002 |
Etoposide in the treatment of non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Etoposide; Humans; Lymphoma, Non-Hodgkin; Salvage Therapy | 1992 |
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Remission Induction; Survival Rate; Vincristine | 1991 |
The evolving role of etoposide in the management of lymphomas and Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin | 1991 |
European experience with ifosfamide in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Europe; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone | 1989 |
Treatment of AIDS and its attendant malignancies.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease Susceptibility; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neutropenia; Sarcoma, Kaposi; Vinblastine; Vincristine; Zidovudine | 1989 |
351 trial(s) available for etoposide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Mul
Topics: Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Busulfan; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Transplantation, Autologous | 2023 |
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Leukocytes, Mononuclear; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prospective Studies; Proteasome Endopeptidase Complex; Rituximab | 2023 |
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Busulfan; Combined Modality Therapy; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Premedication; Progression-Free Survival; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2020 |
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Etoposide; HIV Infections; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Prospective Studies; Rituximab; Vincristine | 2021 |
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; DNA, Viral; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Genes, myc; Herpesviridae Infections; Herpesvirus 4, Human; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisone; Progression-Free Survival; Prospective Studies; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine; Viral Load; Vorinostat | 2020 |
Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Double-Blind Method; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Lymphoma, Non-Hodgkin; Male; Organophosphorus Compounds; Podophyllotoxin; Prognosis; Thymidine Kinase | 2021 |
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Carboplatin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy | 2021 |
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2022 |
Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction | 2018 |
Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Non-Hodgkin; Prednisone; Vincristine | 2020 |
Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Treatment Outcome; Young Adult | 2013 |
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Risk Factors; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Time Factors; Transplantation, Autologous | 2015 |
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytokines; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphocyte Activation; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vincristine | 2016 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thiotepa; Transplantation, Autologous | 2016 |
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Infusions, Intravenous; Injections; Leukocyte Count; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Platelet Count; Prednisone; Survival Analysis | 2008 |
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Survival Rate; Treatment Outcome; Vincristine | 2008 |
Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Peripheral Blood Stem Cell Transplantation; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2008 |
A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Survival Rate | 2009 |
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome | 2008 |
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Female; Humans; Ifosfamide; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Vinblastine; Vinorelbine; Young Adult | 2008 |
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recombinant Proteins; Treatment Outcome; Vincristine | 2009 |
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infections; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Prognosis; Recombinant Proteins; Survival Rate; Vincristine; Young Adult | 2010 |
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fever; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Peripheral Nervous System Diseases; Prednisolone; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome; Vincristine | 2010 |
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Free Radical Scavengers; Glutathione; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Razoxane; Time Factors; Uric Acid; Vincristine | 2010 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult | 2010 |
Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lung Diseases; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2011 |
Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Quality of Life; Remission Induction; Risk Factors; Rituximab; Transplantation, Autologous | 2011 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mouthwashes; Multiple Myeloma; Stomatitis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2011 |
A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Salvage Therapy; Young Adult | 2012 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Sample Size; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrosourea Compounds; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2012 |
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Radioimmunotherapy; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Survival Analysis | 2002 |
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Vincristine | 2002 |
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Salvage Therapy; Survival Rate; Time Factors; Treatment Failure; Vincristine | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Topotecan | 2002 |
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Germany; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisolone; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Stem Cells; Time Factors | 2002 |
Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis | 2002 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Injections, Subcutaneous; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2003 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Platelets; Carmustine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Liver Diseases; Lung Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Etoposide; Hodgkin Disease; Humans; Life Expectancy; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Multiple Myeloma; Organophosphorus Compounds; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2003 |
[Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine | 2003 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphocytosis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; T-Lymphocytes | 2003 |
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Germany; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Prednisolone; Prednisone; Recombinant Proteins; Survival Rate; Vincristine | 2003 |
First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vincristine | 2003 |
Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis | 2003 |
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Survival Rate; Transplantation, Autologous | 2003 |
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Survival; Etoposide; Half-Life; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Middle Aged; Tumor Cells, Cultured | 2004 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Injections, Spinal; Lenograstim; Leucovorin; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prognosis; Recombinant Proteins; Salvage Therapy; Sepsis; Treatment Outcome; Vincristine | 2003 |
A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Mediastinal Neoplasms; Methotrexate; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome; Vincristine | 2004 |
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Conformal; Recurrence; Statistics as Topic; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Italy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Catechols; Child; Etoposide; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Neoplasms; Sarcoma, Ewing; Time Factors | 2004 |
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Etoposide; Humans; Ifosfamide; Interleukin-2; Lymphoma, Non-Hodgkin; Middle Aged; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2004 |
[Mobilization of autologous peripheral blood stem cells with etoposide and recombinant human granulocyte colony stimulating factor in malignant tumor patients].
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins | 2004 |
Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Appetite; Bleomycin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasm Staging; Pain; Prednisone; Quality of Life; Sleep; Surveys and Questionnaires; Vinblastine; Vincristine | 2004 |
Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Vaccines; Humans; Hydrocortisone; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Treatment Outcome; Venezuela; Vincristine | 2004 |
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2004 |
High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2005 |
Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Radiotherapy Dosage; Recurrence; Survival Rate | 2005 |
[VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2005 |
Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Recombinant Proteins; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncolo
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radioimmunotherapy; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Yttrium Radioisotopes | 2005 |
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Etoposide; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Pyruvaldehyde; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis | 2005 |
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous | 2005 |
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Lymphocyte Count; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vincristine | 2005 |
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytarabine; Developing Countries; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive mal
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Radiotherapy; Survival Analysis; Survivors; Vincristine | 2005 |
Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Remission Induction; Risk Factors; Transplantation, Autologous; Vincristine | 2006 |
A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Prednisolone; Procarbazine; Treatment Outcome; Vincristine; Vindesine | 2006 |
[Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pulse Therapy, Drug; Remission Induction; Risk; Survival Rate; Treatment Outcome; Vincristine | 2005 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Prednisone; Proportional Hazards Models; Rituximab; Time Factors; Treatment Outcome; Vincristine | 2006 |
Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Rituximab; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Neutropenia; Prednisolone; Remission Induction; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome; Vincristine | 2006 |
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease Progression; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Salvage Therapy; Survival Analysis; Treatment Failure | 2006 |
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Female; Health Surveys; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Risk Factors; Survival Rate; Vincristine | 2007 |
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Sepsis; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2007 |
CMED in the treatment of nasal natural killer cell lymphoma with distant metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Humans; Killer Cells, Natural; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Nose Neoplasms; Radiotherapy, Adjuvant; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Software; Vincristine | 2008 |
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; Vincristine | 2008 |
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Erythrocyte Transfusion; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Platelet Transfusion; Prednisolone; Remission Induction; Vincristine | 2008 |
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous | 2008 |
Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Middle Aged; Prednisolone; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic; Vincristine | 2008 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 1995 |
P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunologic Factors; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Survival Analysis | 1993 |
Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Vincristine | 1994 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Neoplasm Staging; Oncogenes; Polymerase Chain Reaction; Prednisone; Procarbazine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Remission Induction; Treatment Outcome; Vincristine | 1994 |
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisone; Remission Induction; Survival Analysis; Treatment Failure; Vincristine | 1994 |
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Life Tables; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Remission Induction; Survival Analysis; Teniposide; Thrombocytopenia; Treatment Outcome; Vincristine | 1994 |
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Multivariate Analysis; Prednisone; Procarbazine; Prognosis; Prospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1994 |
Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Platelets; Bone Marrow Transplantation; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Neutropenia; Neutrophils; Platelet Count; Prednisolone; Retrospective Studies; Risk Factors; Vincristine; Vindesine | 1994 |
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vincristine | 1994 |
High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Movement; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prognosis; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Risk Factors; Transplantation, Autologous; Vindesine | 1994 |
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Prednisone; Procarbazine; Prognosis; Prospective Studies; Survival Analysis; Vincristine | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vincristine | 1994 |
Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Salvage Therapy; Treatment Outcome | 1994 |
P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Neutropenia; Prednisone; Prognosis; Remission Induction; Survival Rate; Vinblastine | 1994 |
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Platelet Count | 1995 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Karnofsky Performance Status; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Treatment Failure; Vincristine | 1995 |
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Bone Marrow Purging; Carmustine; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplastic Stem Cells; Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Translocation, Genetic; Treatment Outcome; Whole-Body Irradiation | 1995 |
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Neutropenia; Retrospective Studies; Salvage Therapy | 1995 |
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Palliative Care; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia | 1995 |
Peripheral blood stem cell mobilization following salvage chemotherapy (IAPVP-16) plus granulocyte colony-stimulating factor and autografting for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Salvage Therapy; Transplantation, Autologous | 1995 |
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Europe; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Recombinant Proteins; Remission Induction; Survival Rate; Teniposide; Vincristine | 1995 |
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymerase Chain Reaction; Prednisone; Remission Induction; Stereoisomerism; Verapamil; Vincristine | 1995 |
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Vincristine | 1993 |
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisone; Recurrence; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Monocytes; Recombinant Proteins; Time Factors; Vincristine | 1993 |
[NEO-MACOP-B chemotherapy for the treatment of advanced-stage aggressive non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Vincristine | 1993 |
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; France; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prognosis; Remission Induction; Survival Rate; Transplantation, Autologous; Vindesine | 1993 |
Improved treatment results of non-Hodgkin's lymphoma in children: a report from the Children's Cancer and Leukemia Study Group of Japan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Japan; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Prednisolone; Remission Induction; Vincristine | 1995 |
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mouth Mucosa; Recurrence; Remission Induction; Risk Factors; Stomatitis; Survival Analysis | 1995 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Tolerance; Etoposide; Female; Germinoma; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Ovarian Neoplasms; Prognosis; Sarcoma; Testicular Neoplasms; Transplantation, Autologous | 1995 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschool; Clinical Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infant; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Time Factors | 1995 |
Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Prednisone; Recurrence; Survival Analysis; Treatment Outcome; Vincristine | 1995 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Transplantation, Homologous | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 1995 |
High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 1993 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Hypotension; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous | 1994 |
A six-drug regimen (MAPECO) for intermediate or high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Vincristine | 1994 |
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; L-Lactate Dehydrogenase; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vindesine | 1994 |
Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphocyte Subsets; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Quality of Life | 1994 |
Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recombinant Proteins; Recurrence; Safety; Survival Rate; Transplantation, Autologous | 1994 |
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radiotherapy Dosage; Recurrence; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1994 |
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1994 |
[Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Treatment Outcome | 1994 |
Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednimustine; Prospective Studies; Remission Induction | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies | 1994 |
Phase I-II trial of high dose Ara-C, carboplatinum, etoposide and steroids in patients with refractory or relapsed lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone Hemisuccinate; Middle Aged | 1994 |
Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vincristine; Vindesine | 1994 |
Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study.
Topics: Adult; Bone Marrow; Carcinoma, Small Cell; Drug Administration Schedule; Drug Tolerance; Erythrocyte Transfusion; Etoposide; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Platelet Transfusion | 1994 |
NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Heart Failure; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 1994 |
Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Unknown Primary; Retrospective Studies; Vincristine | 1994 |
[A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction | 1994 |
EPIC: an effective low toxicity regimen for relapsing lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug Administration Schedule; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone | 1993 |
Propantheline prevention of mucositis from etoposide.
Topics: Adult; Bone Marrow Purging; Bone Marrow Transplantation; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mouth Mucosa; Preoperative Care; Propantheline; Stomatitis | 1993 |
A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Remission Induction | 1993 |
[Comparative study of 1st generation versus 2d generation (CAVPE) combinations in intermediate and high-grade lymphomas].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 1993 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8351.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 1993 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Feasibility Studies; Female; Folic Acid; Hematologic Diseases; Humans; Ifosfamide; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisolone; Remission Induction; Risk Factors; Survival Rate; Vincristine | 1996 |
Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vincristine | 1995 |
ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Hemoglobins; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Prednisone; Vincristine | 1995 |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Hemorrhage; Humans; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prospective Studies; Radiotherapy, Adjuvant; Stomach Neoplasms; Vincristine | 1995 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy | 1995 |
A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neoplasm Staging; Prednisone | 1995 |
Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisone; Recombinant Proteins; Remission Induction; Vincristine | 1995 |
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Blood Transfusion; Breast Neoplasms; Cisplatin; Cyclophosphamide; Double-Blind Method; Etoposide; Female; Gastrointestinal Diseases; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Length of Stay; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Platelet Count; Thrombocytopenia; Treatment Outcome | 1996 |
A weekly alternating chemotherapy regimen with low toxicity for the treatment of aggressive lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Remission Induction; Treatment Outcome; Vincristine | 1996 |
Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Foot Diseases; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Infant; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Pain; Peripheral Nervous System Diseases; Vincristine | 1996 |
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Prednisone; Survival Analysis; Thrombocytopenia; Vincristine | 1996 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Whole-Body Irradiation | 1996 |
Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Disease Progression; Disease Susceptibility; Etoposide; Female; Gastrointestinal Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisone; Remission Induction; Salvage Therapy | 1996 |
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter s
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Salvage Therapy; Vincristine | 1996 |
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisolone; Prognosis; Survival Rate; Transplantation, Autologous; Vincristine | 1996 |
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the W
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Immunologic Factors; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Prognosis; Recombinant Proteins; Survival Analysis; Survival Rate; Vincristine | 1996 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednimustine; Prognosis; Prospective Studies; Recurrence; Survival Rate | 1996 |
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Epidural Space; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Middle Aged; Neutropenia; Ondansetron; Retrospective Studies; Salvage Therapy; Spinal Cord Neoplasms; Treatment Outcome; Vincristine | 1996 |
Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pilot Projects; Prednisone; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Thrombocytopenia; Vincristine | 1995 |
A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Survival Analysis; Vincristine | 1996 |
Studies to determine if IL-2 can prevent relapses in post-transplant NHL and AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Recurrence; Remission Induction; Whole-Body Irradiation | 1996 |
Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Rate; Vincristine | 1995 |
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Bleomycin; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ketoconazole; Lymphoma, Non-Hodgkin; Male; Mycoses; Neoplasm Staging; Ofloxacin; Prednisone; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate; Vinblastine | 1996 |
Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Cell Division; Cyclophosphamide; Cytarabine; Dexamethasone; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Flow Cytometry; Humans; Leucovorin; Life Tables; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vincristine | 1996 |
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Piperazines; Recurrence; Salvage Therapy; Topoisomerase II Inhibitors | 1996 |
Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Survival Analysis | 1996 |
CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 1996 |
A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Prospective Studies | 1996 |
Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Treatment Outcome; Vincristine | 1996 |
[Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Stomatitis; Survival Analysis; Vomiting; Waldenstrom Macroglobulinemia | 1997 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Individuality; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1997 |
Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins; Stem Cell Factor | 1997 |
Consolidation therapy with idarubicin, cisplatin and prednisone (CIP) after P-VABEC regimen in the treatment of intermediate and high grade non-Hodgkin's lymphoma of the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Bone Marrow; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Life Tables; Lymphoma, Non-Hodgkin; Male; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 1997 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Neutropenia; Patient Selection; Recombinant Proteins; Thiotepa | 1997 |
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Prednisone; Treatment Outcome; Vincristine | 1997 |
Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP).
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Mediastinal Neoplasms; Middle Aged; Recombinant Proteins; Remission Induction | 1997 |
Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Resistance, Neoplasm; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Recurrence; Remission Induction; Survival Analysis; Thrombocytopenia; Time Factors | 1997 |
A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Thiotepa; Transplantation, Autologous | 1997 |
[Biweekly CHOP-E chemotherapy for aggressive non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Recombinant Proteins; Remission Induction; Vincristine | 1997 |
Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cell Separation; Combined Modality Therapy; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous | 1997 |
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Prospective Studies; Transplantation, Autologous | 1997 |
Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome | 1997 |
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Methylprednisolone; Middle Aged; Prednisolone; Survival Rate; Vincristine; Vindesine | 1997 |
Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Recombinant Proteins; Recurrence; Salvage Therapy | 1997 |
Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Child; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Treatment Outcome | 1997 |
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Filgrastim; Follow-Up Studies; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Leucovorin; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Recombinant Proteins; Treatment Outcome; Vincristine | 1997 |
Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 1997 |
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Recurrence; Salvage Therapy | 1997 |
Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisolone; Recurrence; Vincristine | 1997 |
High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Transplantation, Autologous | 1997 |
A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemokine CCL3; Chemokine CCL4; Cyclophosphamide; Etoposide; Female; Growth Inhibitors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Macrophage Inflammatory Proteins; Male; Middle Aged; Platelet Count; Stomatitis | 1997 |
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednimustine; Prednisone; Vincristine | 1998 |
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
CHOP therapy: has shorter-course therapy had an impact on lymphomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisone; Randomized Controlled Trials as Topic; Time Factors; Vincristine | 1998 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 1998 |
A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1998 |
[Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Serotonin Antagonists; Vincristine; Vomiting | 1998 |
Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Recombinant Proteins; Vincristine | 1998 |
Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; HIV; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Recombinant Proteins; Retrospective Studies; Treatment Outcome; Vincristine | 1998 |
[EPOCH therapy for relapsed/refractory lymphoid malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Treatment Outcome; Vincristine | 1998 |
[Treatment of children with non-Hodgkin's lymphoma with CCLSG NHL 855/890 protocols long-term outcome and incidence of secondary malignancies].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydrocortisone; Infant; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Prednisolone; Remission Induction; Treatment Outcome; Vincristine | 1998 |
Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; HIV Protease Inhibitors; Humans; Logistic Models; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Saquinavir; Treatment Outcome | 1998 |
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan | 1998 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Vincristine | 1998 |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hem
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Data Interpretation, Statistical; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Survival Analysis; Time Factors; Vincristine | 1998 |
Etoposide and idarubicin in a modified CHOP-like regimen (VICED) for aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisolone; Prospective Studies; Survival Rate; United Kingdom; Vincristine | 1998 |
VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Salvage Therapy; Survival Rate; Vincristine | 1998 |
[Bleomycin, adriamycin, cyclophosphamide, vincristine, deacadron, etoposide (BACOD-E) chemotherapy for the treatment of non-Hodgkin's lymphoma: long-term survival rate and complications].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Survivors; Vincristine | 1998 |
Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Prospective Studies; Treatment Outcome | 1998 |
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms | 1998 |
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Interactions; Etoposide; Humans; Irinotecan; Liver; Lymphoma, Non-Hodgkin; Middle Aged; Topoisomerase I Inhibitors | 1998 |
The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Italy; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Severity of Illness Index; Survival Analysis; Treatment Outcome | 1998 |
Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Interleukin-3; Leukocyte Count; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Platelet Count; Premedication; Safety; Thrombocytopenia; Treatment Outcome | 1997 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Transplantation Conditioning | 1998 |
VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Treatment Outcome; Vincristine | 1998 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Analysis; Vincristine | 1998 |
[Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Topics: Adolescent; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Vincristine | 1998 |
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis | 1998 |
Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; Japan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Rate; Time Factors | 1998 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Salvage Therapy | 1999 |
ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 1999 |
A phase-II study with idarubicin, etoposide and prednisone (IVPP), in patients with refractory or early relapsed intermediate or high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence | 1999 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug Resistance, Multiple; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors | 1999 |
Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Analysis | 1999 |
Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence | 1999 |
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Vincristine | 1999 |
Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Pilot Projects; Recurrence; Transplantation Conditioning | 1999 |
Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Filgrastim; Genes, Immunoglobulin; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Thiotepa; Treatment Outcome | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Infant; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasm Staging; Prednisolone; Treatment Outcome; Vincristine | 1999 |
A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Treatment Failure; Treatment Outcome; Vincristine | 1999 |
[Combined modality therapy for malignant lymphoma of the primary central nervous system: a preliminary report of a new chemotherapeutic regimen with "PEACE"].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Procarbazine; Treatment Outcome | 1999 |
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Movement; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Stem Cells | 1999 |
CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Analysis; Vincristine | 1999 |
Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Vincristine | 2000 |
VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2000 |
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation, Autologous | 1999 |
Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 1999 |
A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distribution; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Prednisolone; Severity of Illness Index; Survival Analysis; United Kingdom; Vincristine | 2000 |
Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Models, Theoretical; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors | 2000 |
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Transfusion; Lung; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Transfusion; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Salvage Therapy; Survival Analysis | 2000 |
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Recombinant Proteins; Remission Induction; Vincristine | 2000 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recombinant Proteins; Regression Analysis; Survival Rate; Transplantation, Autologous | 2000 |
Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Survival Analysis; Transplantation, Autologous | 2000 |
[Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Vincristine | 1997 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; L-Lactate Dehydrogenase; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prednisone; Prognosis; Safety; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Statistics, Nonparametric; Vindesine | 2000 |
Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma | 2000 |
CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Gr
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Prednisolone; Prognosis; Remission Induction; Risk Factors; Treatment Outcome; Vincristine | 2000 |
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrosourea Compounds; Prednisone; Survival Rate; Vincristine | 2000 |
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 2000 |
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Salvage Therapy; Stroke Volume; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Recurrence; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Culture Techniques; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Recombinant Proteins; Time Factors; Vincristine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Salvage Therapy; Thiotepa | 2001 |
Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Female; Humans; Isoenzymes; Lymphoma, Non-Hodgkin; Male; Middle Aged; RNA, Messenger; Topotecan; Treatment Outcome | 2001 |
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome | 2000 |
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
Topics: Actuarial Analysis; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Survival Rate; Treatment Outcome | 2001 |
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Retrospective Studies; Salvage Therapy; Vincristine | 2001 |
Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2001 |
Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome | 2001 |
The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antifungal Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Atovaquone; Child; Child, Preschool; Cross-Over Studies; Drug Interactions; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Naphthoquinones; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Trimethoprim, Sulfamethoxazole Drug Combination | 2001 |
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisone; Treatment Outcome; Vincristine | 2001 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Sex Factors | 2001 |
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi-Square Distribution; Cisplatin; Cost-Benefit Analysis; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prospective Studies; Quality of Life; Recurrence; Statistics, Nonparametric; Survival Rate; Transplantation, Autologous | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infections; Injections, Spinal; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Survival Analysis; Thrombocytopenia; Vincristine | 2001 |
CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Prednisone; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Female; Growth Substances; Humans; Hydro-Lyases; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Prednisone; Survival Rate; Treatment Outcome; Vincristine | 2001 |
Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human; Cyclophosphamide; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Life Tables; Lymphoma, Non-Hodgkin; Metaphase; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Prednisolone; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2001 |
Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Germany; Humans; Life Tables; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Lomustine; Lung Diseases, Interstitial; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Therapeutic Equivalency; Transplantation, Autologous | 2001 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2002 |
Cytosine arabinoside and etoposide (CARE) in relapsed and refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged | 1992 |
Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Leukopenia; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Prospective Studies; Time Factors; Vincristine | 1992 |
The capacity of peripheral blood stem cells mobilised with chemotherapy plus G-CSF to repopulate irradiated marrow stroma in vitro is similar to that of bone marrow.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Cells; Cells, Cultured; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vincristine | 1992 |
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Lymphoma, Non-Hodgkin; Middle Aged; Neutropenia; Survival Rate; Vincristine | 1992 |
Chronic etoposide schedules in the treatment of non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radiography | 1992 |
[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunoblastic Lymphadenopathy; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone | 1992 |
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous; Whole-Body Irradiation | 1992 |
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic System; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation, Autologous | 1991 |
Combination chemotherapy for advanced diffuse large cell lymphoma. The adverse effects of bone marrow invasion, gastrointestinal tract involvement or high bulk disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Carubicin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Invasiveness; Prednisone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Vincristine | 1990 |
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cause of Death; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Remission Induction; Survival Rate; Vincristine | 1990 |
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 1991 |
[Non-Hodgkin's lymphomas. Results of alternating chemotherapy versus sequential chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Life Tables; Lymphoma, Non-Hodgkin; Methotrexate; Mexico; Prednisone; Remission Induction; Survival Rate; Vincristine | 1990 |
Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Gro
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Random Allocation; Vincristine | 1990 |
Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Electrophysiology; Etoposide; Gangliosides; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Motor Activity; Muscular Diseases; Neurologic Examination; Peripheral Nervous System Diseases; Prospective Studies; Random Allocation; Sensory Thresholds; Vincristine | 1991 |
Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Middle Aged; Prednisone; Procarbazine; Remission Induction; Survival Rate; Vincristine | 1991 |
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 1991 |
ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Prednisolone; Prednisone; Procarbazine; Vincristine | 1991 |
ProMACE-cytaBOM versus MACOP-B in intermediate and high grade NHL. Preliminary results of a prospective randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoiesis; Humans; Inflammation; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mucous Membrane; Prednisolone; Prednisone; Prognosis; Prospective Studies; Survival Analysis; Vincristine | 1991 |
A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednimustine; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
ProMACE-C-MOPP in aggressive non-Hodgkin's lymphoma. Long-term results in 45 patients treated in a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Procarbazine; Vincristine | 1991 |
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Transplantation, Autologous | 1991 |
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Mitoguazone; Prognosis | 1991 |
PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Prospective Studies; Random Allocation; Remission Induction; Survival Rate; Transplantation, Autologous | 1991 |
Sequential versus alternating chemotherapy for high-grade non-Hodgkin's lymphomas: preliminary results of a phase III multicentre trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Randomized Controlled Trials as Topic; Vincristine; Vindesine | 1990 |
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Time Factors; Vincristine | 1987 |
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Procarbazine; Vincristine | 1988 |
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Prednisone; Procarbazine; Vincristine | 1988 |
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Evaluation Studies as Topic; Humans; Leucovorin; Leukemia; Leukemia, Radiation-Induced; Lymph Nodes; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Palliative Care; Prednisone; Procarbazine; Random Allocation; Vincristine | 1988 |
[Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Vincristine | 1989 |
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Middle Aged; Prednisone; Procarbazine; Prospective Studies; Risk Factors; Vincristine | 1989 |
[Aclarubicin-combined combination chemotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Prednisolone; Recurrence; Remission Induction; T-Lymphocytes; Vinblastine; Vindesine | 1989 |
CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Germany, West; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Prednisolone; Prednisone; Survival Rate; Vincristine | 1989 |
Infusion of etoposide and vincristine in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vincristine | 1989 |
[Clinical trial of high-dose etoposide].
Topics: Adult; Aged; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hodgkin Disease; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1988 |
[A comparative study of ABEP and ACOPE in the treatment of non-Hodgkin's lymphoma CS IV].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisolone; Prospective Studies; Random Allocation; Remission Induction; Vincristine | 1988 |
[Multicenter study of the treatment of highly malignant non-Hodgkin's lymphomas with polychemotherapy (CHOPV) and irradiation].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Vincristine | 1987 |
[Clinical study of non-Hodgkin's lymphoma--results of the Kanazawa University-Kurume University Cooperative Study on Malignant Lymphomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisolone; Vincristine | 1986 |
403 other study(ies) available for etoposide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Retrospective Studies; Rituximab | 2022 |
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Neutrophils; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail Elderly; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Retrospective Studies; Rituximab | 2022 |
Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy.
Topics: Adult; Cisplatin; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methylprednisolone | 2022 |
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Rituximab; Salvage Therapy | 2022 |
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Latin America; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Recurrence; Registries; Retrospective Studies; Rituximab; Vincristine | 2022 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2023 |
PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Retrospective Studies; Rituximab | 2023 |
In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
Topics: Cyclophosphamide; Doxorubicin; Drug Stability; Epirubicin; Etoposide; Humans; Infusion Pumps; Lymphoma, Non-Hodgkin; Prednisone; Vincristine; Vindesine | 2019 |
Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Malawi; Male; Middle Aged; Neutropenia; Prednisone; Progression-Free Survival; RNA, Viral; Vincristine; Young Adult | 2020 |
The justification of vincristine dose capping: tradition, tradition…tradition!
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Incidence; Lymphoma, Non-Hodgkin; Peripheral Nervous System Diseases; Prednisone; Vincristine | 2020 |
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hydrocortisone; Lymphoma, Non-Hodgkin; Male; Methotrexate; Piperazines; Salvage Therapy; Treatment Outcome; Vincristine | 2020 |
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy | 2020 |
Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Animals; Apoptosis; Bone Marrow; Cell Line; Cell Proliferation; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Interleukin-8; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Mesenchymal Stem Cells; Mice; Middle Aged; Models, Animal; Peripheral Blood Stem Cell Transplantation; Primary Cell Culture; Retrospective Studies; Transplantation, Autologous; Young Adult | 2020 |
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Dexamethasone; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Young Adult | 2020 |
Individual prediction of thrombocytopenia at next chemotherapy cycle: Evaluation of dynamic model performances.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Lymphoma, Non-Hodgkin; Thrombocytopenia | 2021 |
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Rituximab; Treatment Outcome | 2021 |
MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Piperazines; Prognosis; Proportional Hazards Models; Recurrence; Salvage Therapy; Treatment Outcome; Vincristine | 2021 |
Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Polyethylene Glycols; Prednisone; Recombinant Proteins; Retrospective Studies; Vincristine | 2021 |
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Premedication; Retreatment; Risk Factors; Rituximab; Survival Analysis; Treatment Outcome; Vincristine; Young Adult | 2017 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Hyperglycemia; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2018 |
Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2018 |
Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Registries; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2018 |
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2019 |
[Clinical observation for NAPD regimen in the treatment of 67 cases of recurrent refractory non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2019 |
[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Febrile Neutropenia; Female; Filgrastim; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2019 |
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous | 2019 |
[Triple expressor lymphoma in a kidney transplant patient].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Etoposide; Genes, myc; Humans; Kidney Transplantation; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Vincristine | 2019 |
Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Autophagy-Related Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Survival Analysis; Treatment Outcome | 2019 |
High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Recurrence; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Practice Guidelines as Topic; Prednisone; Prognosis; Radioimmunotherapy; Rituximab; Vincristine | 2004 |
Flying solo: chemotherapy without radiation for primary CNS lymphoma.
Topics: Central Nervous System Neoplasms; Cranial Irradiation; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Conso
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Prednisone; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Vincristine | 2014 |
AIDS-lymphoma (ARL): one more step along the way.
Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; HIV Infections; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vincristine | 2013 |
Optimal autologous peripheral blood progenitor cell mobilization involves more than the CD34+yield.
Topics: Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male | 2014 |
Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.
Topics: Adolescent; Adult; Aged; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Evidence-Based Medicine; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Practice Guidelines as Topic; Prednisolone; Prednisone; Vincristine | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Prognosis; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2015 |
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, bcl-2; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Serum Albumin; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Frail Elderly; Geriatric Assessment; Glyoxal; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Multivariate Analysis; Neoplasm Grading; Prednimustine; Prednisone; Prospective Studies; Republic of Korea; Treatment Outcome; Vincristine | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Nervous System Neoplasms; Cohort Studies; Cyclophosphamide; Cytarabine; Databases, Factual; Dexamethasone; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, bcl-2; Genes, myc; Germinal Center; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-6; Rituximab; Survival Rate; Vincristine | 2016 |
False-Positive 18F-FDG PET/CT Imaging: Dramatic "Flare Response" After Rituximab Administration.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Methylprednisolone; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Rituximab; Tomography, X-Ray Computed | 2016 |
[Clinical Study of Non Hodgkin's Lymphoma Treated with Enhanced Chemotherapy Regimen and Increased Treatment Courses].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Prednisone; Prognosis; Recurrence; Remission Induction; Vincristine | 2015 |
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisone; Prognosis; Rituximab; Survival Rate; T-Lymphocytes; Treatment Outcome; Vincristine | 2016 |
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Survival Rate; Transplantation Conditioning; Young Adult | 2016 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome | 2016 |
Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Topics: Antigens, CD34; Antineoplastic Agents; Epirubicin; Etoposide; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cells; Prospective Studies; Salvage Therapy | 2016 |
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Liver Function Tests; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Transfusion; Carboplatin; Cyclams; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Young Adult | 2016 |
Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hospitalization; Humans; Inpatients; Lymphoma, Non-Hodgkin; Male; Middle Aged; Outpatients; Prednisone; Prospective Studies; Retrospective Studies; Vincristine | 2017 |
The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymp
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Recurrence; Vascular Endothelial Growth Factor A; Young Adult | 2016 |
[Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.]
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Transplantation, Autologous; Young Adult | 2016 |
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Methotrexate; Polyethylene Glycols; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vincristine | 2017 |
Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Peripheral Blood Stem Cell Transplantation | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Stomatitis; Transplantation Conditioning | 2009 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
Clinical investigations in aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisolone; Prednisone; Rituximab; Vincristine | 2008 |
Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.
Topics: Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Case-Control Studies; Cell Cycle Proteins; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nuclear Proteins; Nucleic Acid Conformation; Polymorphism, Single Nucleotide; RNA, Messenger | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult | 2009 |
[Non-Hodgkin's primitive lymphoma of the testis: long-term prognosis associated with treatment combining systemic and intrathecal chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Testicular Neoplasms; Vincristine | 2009 |
Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stem Cell Transplantation; Survival Analysis; Treatment Failure | 2009 |
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2009 |
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Central Nervous System Neoplasms; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab; Stem Cell Transplantation | 2009 |
Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy | 2009 |
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
Topics: Administration, Oral; Adolescent; Adult; Africa South of the Sahara; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Kenya; Lomustine; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Procarbazine; Treatment Outcome; Uganda; Virus Replication; Young Adult | 2009 |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Glucocorticoids; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy | 2009 |
Lymphoma in the Waldeyer ring: a great masquerader.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Endoscopy; Etoposide; Head and Neck Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Nasopharyngeal Neoplasms; Prednisone; Prognosis; Rituximab; Tonsillar Neoplasms; Treatment Outcome; Vincristine | 2009 |
[One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; International Cooperation; Kaplan-Meier Estimate; Leiomyosarcoma; Lymphoma, Non-Hodgkin; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2009 |
Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.
Topics: Androstadienes; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Etoposide; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Lymphoma, Non-Hodgkin; Membrane Proteins; Phosphorylation; Proto-Oncogene Proteins; Time Factors; Up-Regulation; Wortmannin | 2010 |
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2010 |
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multivariate Analysis; Prednisone; Radiotherapy; Retrospective Studies; Treatment Outcome; Vincristine | 2010 |
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Postoperative Period; Prednisone; Preoperative Period; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2010 |
Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Manitoba; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Radiation Pneumonitis; Retrospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2010 |
A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gene Expression; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; NADPH Oxidases; Polymorphism, Single Nucleotide; Prednisolone; Protein Subunits; RNA, Messenger; Treatment Outcome; Vincristine; Young Adult | 2010 |
[Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Prospective Studies; Remission Induction; Rituximab; Stem Cell Transplantation; Survival Analysis; Tunisia; Vincristine; Young Adult | 2010 |
Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisolone; Remission Induction; Sirolimus; Tongue Neoplasms; Treatment Failure; Treatment Outcome; Vincristine | 2011 |
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Recurrence; Salvage Therapy | 2011 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Glyoxal; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednimustine; Prednisone; Procarbazine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; Vinblastine; Vincristine | 2011 |
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Monitoring, Physiologic; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Time Factors; Vincristine; Young Adult | 2011 |
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Disease Progression; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Radiotherapy; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Topics: Adolescent; Adult; Age of Onset; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Germany; Humans; International Cooperation; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Grading; Neoplasm Invasiveness; Prednisolone; Prednisone; Rituximab; Societies, Medical; Vincristine; Young Adult | 2012 |
Retrospective analysis of an efficient peripheral blood stem cell collection and the relation between infused cell dose and clinical outcome in patients with malignant lymphoma and multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Drug Dosage Calculations; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.
Topics: Aged; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cyclophosphamide; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Meningitis, Cryptococcal; Osteomyelitis; Prednisone; Procarbazine | 2012 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine | 2012 |
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Autografts; Benzylamines; Costs and Cost Analysis; Cyclams; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2013 |
Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2012 |
Modified BEAM conditioning regimen in patients with Hodgkin and non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Melphalan | 2012 |
[Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myelomonocytic, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary; Remission Induction; Translocation, Genetic | 2002 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2002 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 11; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pelvis; Pregnancy; Pregnancy Complications, Neoplastic; Transplantation, Autologous | 2002 |
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Humans; Hypopituitarism; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vincristine | 2002 |
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors | 2002 |
ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cytarabine; Disease-Free Survival; Drug Tolerance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy | 2002 |
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Survival Analysis | 2002 |
A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation.
Topics: Etoposide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mouth Mucosa; Multivariate Analysis; Prospective Studies; Radiotherapy, Adjuvant; Risk Factors; Stomatitis; Transplantation, Autologous | 2002 |
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Survival Rate; Vinblastine | 2002 |
Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Germany; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Prednisolone; Randomized Controlled Trials as Topic; Risk; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2002 |
Coeliac disease following high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Celiac Disease; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Diarrhea; Diet; Doxorubicin; Etoposide; Glutens; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Morbidity; Prednisolone; Vincristine | 2002 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kuwait; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Mercaptopurine; Mesna; Methotrexate; Neoplasm Staging; Prednisolone; Prednisone; Survival Rate; Thioguanine; Treatment Outcome; Vincristine | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Vincristine | 2003 |
Shorter is not better.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Survival Analysis; Treatment Outcome | 2003 |
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Stem Cell Transplantation; Survival Rate | 2003 |
Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Secondary Prevention; Stem Cell Transplantation | 2003 |
Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Linear Models; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Retrospective Studies; Selenium; Survival Analysis; Vincristine | 2003 |
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prognosis; Treatment Outcome | 2003 |
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Combinations; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pleural Effusion; Prednisone; Tamoxifen; Tegafur; Uracil; Vincristine | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Safety; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunophenotyping; Lymphocyte Depletion; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisolone; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vincristine | 2003 |
[Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Survival Rate; Vincristine | 2003 |
Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-Positive T-Lymphocytes; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Interferon-gamma; Interleukin-4; Intracellular Fluid; Lymphocyte Count; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Th1 Cells; Th2 Cells; Vincristine | 2004 |
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Survival Rate; Time Factors | 2004 |
Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2004 |
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Risk; Time Factors; Treatment Outcome | 2004 |
The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Interleukin-10; Interleukin-2; Interleukin-6; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Prednisone; Prognosis; Regression Analysis; Time Factors; Treatment Outcome; Vincristine | 2004 |
ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous | 2005 |
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Survival Rate; Vincristine | 2005 |
[Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Treatment Outcome | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning | 2005 |
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thrombocytopenia; Transplantation, Autologous | 2005 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infections; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2005 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Melphalan; Middle Aged; Prednisolone; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2005 |
Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin's and non-Hodgkin's lymphoma and a preliminary study on the toxicity of etoposide associated with LDE.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Cholesterol Esters; Cholesterol, LDL; Drug Carriers; Emulsions; Etoposide; Female; Hodgkin Disease; Humans; Kinetics; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Pilot Projects; Receptors, LDL | 2006 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular System; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Heart; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptides; Peptides; Prospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
Salvage combination chemotherapy with cisplatinum, etoposide and bleomycin in refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 1989 |
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies | 2006 |
Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukocyte Count; Leukopenia; Lymphoma, Non-Hodgkin; Male; Mathematics; Middle Aged; Models, Biological; Prednisone; Risk Factors; Severity of Illness Index; Vincristine | 2006 |
Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Stem Cells; Time Factors; Transplantation, Autologous; Treatment Outcome | 2006 |
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Mediastinal Neoplasms; Positron-Emission Tomography; Prednisone; Procarbazine; Thymus Hyperplasia; Tomography, X-Ray Computed; Vinblastine; Vincristine | 2006 |
Retroperitoneal fibrosis after chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Retroperitoneal Fibrosis; Retroperitoneal Neoplasms; Vincristine | 2007 |
[IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoguazone; Recurrence | 2006 |
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Topics: Administration, Oral; Adolescent; Adult; Aged; Busulfan; Chi-Square Distribution; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Secondary Prevention; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Burkitt Lymphoma; Carboplatin; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; False Positive Reactions; Humans; Ifosfamide; Laparoscopy; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Necrosis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Spleen; Splenectomy; Tomography, X-Ray Computed; Unnecessary Procedures; Vincristine | 2006 |
Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gated Blood-Pool Imaging; Heart; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Postoperative Period; Prospective Studies; Protein Precursors; Sensitivity and Specificity; Stroke Volume; Systole; Transplantation, Autologous; Ventricular Dysfunction, Left | 2006 |
Defining the cost of cure: infertility among female survivors of lymphoma.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infertility, Female; Kinetics; Lymphoma, Non-Hodgkin; Menstrual Cycle; Patient Education as Topic; Prednisone; Remission Induction; Risk; Vincristine | 2006 |
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Agents; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Immunologic Factors; Kinetics; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Stem Cells | 2006 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine | 2007 |
[Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nasal Cavity; Neoplasm Recurrence, Local; Neoplasm Staging; Nose Neoplasms; Prednisone; Proportional Hazards Models; Radiotherapy, High-Energy; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vincristine; Young Adult | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Thrombocytopenia; Young Adult | 2006 |
[Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Radiotherapy, Adjuvant; Recurrence; Retrospective Studies; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Mycobacterium tuberculosis; Prednisone; Retrospective Studies; Tuberculosis; Vincristine; Virus Activation | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
[MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Hydrocortisone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Piperazines; Salvage Therapy; Survival Rate; Thrombocytopenia; Vincristine | 2007 |
[Role of amifostine against the effect of etoposide on non-Hodgkin lymphoma bone marrow derived mesenchymal stem cells: an in vitro experiment].
Topics: Adult; Amifostine; Antigens, CD; Apoptosis; Bone Marrow Cells; Cell Proliferation; Cell Separation; Etoposide; Flow Cytometry; HLA-DR Antigens; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Mesenchymal Stem Cells; Middle Aged; Time Factors | 2007 |
Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Models, Statistical; Proportional Hazards Models; Stem Cell Transplantation; Time; Transplantation, Autologous; Treatment Outcome | 2008 |
Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome | 2007 |
Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclins; Cyclophosphamide; Doxorubicin; Drug Synergism; Etoposide; Gossypol; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisolone; Tumor Suppressor Protein p53; Vincristine | 2008 |
Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cellular Senescence; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelopoiesis; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Rituximab; Telomere; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2008 |
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Nimustine; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous | 2008 |
[Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2008 |
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Immunotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2008 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vincristine | 2008 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1995 |
Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Length of Stay; Leukapheresis; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Vincristine | 1993 |
[Successful collection of peripheral blood stem cells mobilized by a combination of G-CSF with high-dose Ara-C or high-dose etoposide].
Topics: Acute Disease; Adolescent; Adult; Blood Component Removal; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Sperm Count; Sperm Motility; Vincristine | 1994 |
Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisone; Vincristine | 1993 |
[Increased blood cell destruction during vigorous regeneration of bone marrow after CAMBO-VIP chemotherapy for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count; Bone Marrow Cells; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Vincristine | 1994 |
Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Vincristine | 1994 |
Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Survival Analysis; Vincristine | 1994 |
Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion, Autologous; Breast Neoplasms; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Immunologic Factors; Leukapheresis; Lymphoma, Non-Hodgkin; Middle Aged; Neutropenia; Ovarian Neoplasms | 1994 |
A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Feasibility Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Vincristine | 1994 |
The response of diffuse large cell and other intermediate grade non-Hodgkin's lymphomas to adriamycin containing combination chemotherapy.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Leucovorin; Lomustine; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Melphalan; Methotrexate; Middle Aged; Phosphoramide Mustards; Prednisolone; Prednisone; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Vincristine | 1994 |
Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blotting, Southern; CD4 Lymphocyte Count; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; DNA, Neoplasm; DNA, Viral; Doxorubicin; Etoposide; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Genes, myc; Granulocyte-Macrophage Colony-Stimulating Factor; Herpesvirus 4, Human; Humans; Immunoglobulin Variable Region; Immunologic Factors; Leucovorin; Life Tables; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Methotrexate; Polymerase Chain Reaction; Prednisone; Proportional Hazards Models; Radiotherapy, Adjuvant; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Treatment Outcome; Vincristine | 1995 |
Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Adhesion Molecules; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Luminescent Measurements; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Proteins; Neutropenia; Neutrophils; Prednisone; Recombinant Proteins; Respiratory Burst; Vincristine | 1995 |
Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation.
Topics: Antigens, CD; Antigens, CD34; Bone Marrow; Bone Marrow Cells; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Separation; Centrifugation, Density Gradient; Colony-Forming Units Assay; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphocyte Depletion; Lymphoma, Non-Hodgkin; Mucins; Povidone; Reference Values; Silicon Dioxide; T-Lymphocytes | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Glyoxal; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednimustine; Prednisolone; Prednisone; Procarbazine; Radiotherapy; Retrospective Studies; Salvage Therapy; Vinblastine; Vincristine | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation, Autologous | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Salvage Therapy; Vincristine | 1995 |
[Daily oral low-dose etoposide therapy for aged patients with relapsed aggressive lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Prednisone; Quality of Life; Recurrence; Remission Induction; Vincristine | 1995 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Interleukin-6; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Non-Hodgkin; Macrophage Colony-Stimulating Factor; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; HIV Seropositivity; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Recurrence; Survival Rate; Vincristine | 1993 |
Clinical trials referral resource. AIDS-related non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Erythropoietin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-3; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Prednisone; Vincristine; Zidovudine | 1993 |
[Chemotherapy for older cancer patients].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Floxuridine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Neoplasms, Multiple Primary; Palliative Care; Quality of Life | 1993 |
[High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine; Whole-Body Irradiation | 1993 |
CHOP versus intensive regimens in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Vincristine | 1993 |
Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Ovarian Diseases; Prednisone; Retrospective Studies; Testicular Diseases; Vincristine | 1993 |
[Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Procarbazine; Recurrence; Remission Induction; Vincristine | 1993 |
Hepatitis after withdrawal of chemotherapy in a patient with chronic hepatitis B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Hepatitis B; Humans; Immunocompromised Host; Lymphoma, Non-Hodgkin; Male; Prednisolone; Vincristine | 1993 |
Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Prognosis; Survival Analysis; Vincristine | 1993 |
[Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy | 1994 |
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation, Homologous; Whole-Body Irradiation | 1995 |
Treatment of aggressive non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged | 1995 |
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cell Count; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Opportunistic Infections; Survival Analysis | 1995 |
Correction to Cancer Therapy Protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methylprednisolone | 1994 |
Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Time Factors; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies.
Topics: Adolescent; Bacterial Infections; Bone Marrow Transplantation; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Infant; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Remission Induction; Stomatitis; Survival Rate; Whole-Body Irradiation | 1994 |
Dosing error in protocol book.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methylprednisolone | 1994 |
ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methylprednisolone; Prognosis; Recurrence; Survival Rate; Treatment Outcome | 1994 |
Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Neoplasm Staging; Prednisone; Vincristine; Vindesine | 1993 |
Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Male; Peripheral Nervous System Diseases; Transplantation, Autologous | 1994 |
Excretion of Ascaris lumbricoides during total body irradiation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gastrointestinal Contents; Humans; Intestinal Diseases, Parasitic; Leucovorin; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Vincristine; Vomiting; Whole-Body Irradiation | 1994 |
Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1994 |
[Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone | 1994 |
E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia | 1994 |
Relapsing chickenpox in a young man with non-Hodgkin's lymphoma.
Topics: Acyclovir; Adult; Antineoplastic Combined Chemotherapy Protocols; Chickenpox; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Herpesvirus 3, Human; Humans; Immunocompromised Host; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Recurrence; Vincristine; Virus Activation | 1994 |
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Transplantation, Autologous | 1993 |
[Dose escalation study of high dose etoposide in autologous hematopoietic stem cell transplantation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation, Autologous | 1993 |
[Chronic daily administration of oral etoposide in elderly relapse or refractory lymphoma].
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Remission Induction | 1994 |
Third generation chemotherapy with P-VABEC for aggressive non-Hodgkin's lymphomas of the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Middle Aged | 1993 |
[A case of gastric malignant lymphoma markedly responding to chronic daily and oral administration of low-dose etoposide].
Topics: Administration, Oral; Aged; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Salvage Therapy; Stomach Neoplasms | 1993 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine | 1993 |
High-dose carboplatin, etoposide and ifosfamide and autologous stem cell rescue in the treatment of non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Transplantation, Autologous | 1993 |
[Successful oral administration of etoposide therapy for refractory malignant lymphoma treated with frequent combination chemotherapy].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Leucovorin; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisone; Recurrence; Salvage Therapy; Vincristine | 1993 |
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Flow Cytometry; Humans; Lomustine; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Procarbazine; Proportional Hazards Models; Quality of Life; Survival Analysis; Treatment Outcome | 1993 |
Prednisolone, cytosine arabinoside, lomustine (CCNU), etoposide and thioguanine (PACET) combination chemotherapy for relapsed or refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisolone; Prognosis; Prospective Studies; Thioguanine | 1993 |
Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction | 1993 |
High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Child; Child, Preschool; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Life Tables; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Risk; Vincristine | 1993 |
IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Pilot Projects; Recombinant Proteins | 1993 |
Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; HIV; HIV Infections; HIV Seropositivity; HTLV-I Infections; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Time Factors | 1993 |
[Spontaneous splenic rupture in a case of non-Hodgkin's lymphoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Splenic Rupture; Vincristine | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Non-Hodgkin; Macrophages; Male; Melphalan | 1995 |
Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF.
Topics: Adult; Bone Marrow; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Phenotype | 1995 |
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Glucocorticoids; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Prospective Studies; Vincristine; Virus Activation | 1996 |
VACOP-B chemotherapy for high grade non-Hodgkin's lymphoma in pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Infant, Newborn; Lymphoma, Non-Hodgkin; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Vincristine | 1995 |
VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Survival Rate; Vincristine | 1995 |
The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Transplantation; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 1996 |
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Thiotepa | 1995 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoguazone; Prospective Studies; Salvage Therapy; Sweden; Transplantation, Autologous; Treatment Outcome | 1996 |
Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Costs and Cost Analysis; Cyclophosphamide; Disposable Equipment; Doxorubicin; Drug Costs; Etoposide; Fees, Medical; Fees, Pharmaceutical; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Models, Economic; Prednisone; Survival Rate; Vincristine | 1996 |
Evaluation of cytosine arabinoside, carboplatin and etoposide chemotherapy in the treatment of relapsing and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Time Factors | 1996 |
[Chemotherapy for two patients with non-Hodgkin's lymphoma in hemodialysis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Kidney Failure, Chronic; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Remission Induction; Renal Dialysis; Vincristine | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disease; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Vincristine | 1996 |
Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Didanosine; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; HIV; HIV Core Protein p24; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Survival Rate; Viremia | 1996 |
Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisone; Recombinant Proteins | 1996 |
Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recombinant Proteins | 1996 |
Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cause of Death; CD4 Lymphocyte Count; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphocyte Subsets; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Risk; Survival Analysis | 1997 |
Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Blood Specimen Collection; Breast Neoplasms; Cryopreservation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1997 |
Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutrophils; Platelet Count; Transplantation Conditioning | 1997 |
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methylprednisolone; Middle Aged; Myeloproliferative Disorders; Neutropenia; Salvage Therapy; Survival Rate; Time Factors | 1997 |
A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Pilot Projects; Prednisone; Remission Induction; Survival Analysis; Treatment Failure; Vincristine | 1997 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine | 1997 |
Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Prednisone; Remission Induction; Sezary Syndrome; Skin Neoplasms; Vincristine | 1997 |
[Effectiveness of prolonged oral therapy with low-dose etoposide in patients aged 85 years and over with non-Hodgkin's lymphoma].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male | 1997 |
High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Prednisone; Procarbazine; Prospective Studies; Radiotherapy, Adjuvant; Stomach Neoplasms; Vincristine | 1996 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 1997 |
Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma.
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis | 1997 |
High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Mitoguazone; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Treatment Failure | 1997 |
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoxantrone; Prognosis; Salvage Therapy; Texas; Treatment Outcome | 1997 |
[Etoposide combination chemotherapy for malignant lymphoma: a report of 91 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vincristine | 1996 |
Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome | 1997 |
[Interstitial pneumonia in patients treated with VACOP-B therapy for malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Diseases, Interstitial; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vincristine | 1998 |
Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Secondary Prevention; Treatment Outcome | 1998 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Partial Thromboplastin Time; Plasminogen; Prednisone; Procarbazine; Protein C; Protein S; Thrombophilia; Time Factors; Vinblastine; Vincristine | 1997 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Salvage Therapy; Time Factors | 1998 |
High incidence of chemotherapy-induced acral erythema in female patients with non-Hodgkin's lymphoma treated with the VACOP-B regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Erythema; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Prednisone; Retrospective Studies; Sex Distribution; Vincristine | 1998 |
Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Transplantation, Autologous; Vincristine | 1998 |
Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pneumonia; Prednisolone; Pulmonary Fibrosis; Vascular Neoplasms; Vincristine | 1998 |
p53 gene mutation in the bone-marrow of a patient with diffuse mixed cell type lymphoma at diagnosis predicting eventual progression to large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; Disease Progression; Etoposide; Fatal Outcome; Genes, p53; Genetic Markers; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mutation; Sequence Analysis, DNA | 1998 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies | 1998 |
[A case of primary malignant lymphoma of the bladder].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Prednisolone; Remission Induction; Urinary Bladder Neoplasms; Vincristine | 1998 |
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Prednisone; Survival Rate; Treatment Outcome; Vincristine | 1998 |
[Intraarterial chemotherapy using a combination of etoposide and cisplatin for recurrent malignant lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cisplatin; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging | 1998 |
High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL-preliminary results.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclosporine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1998 |
Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Drug Evaluation; Drug Monitoring; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged | 1999 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Vincristine | 1999 |
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Middle Aged; Receptors, Retinoic Acid; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 1999 |
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome | 1999 |
[A case of leukemic lymphoma complicated by M-proteinemia: effectiveness of long-term daily administration of oral low-dose etoposide in continuing remission].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Employment; Etoposide; Humans; Immunoglobulin M; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paraproteinemias; Remission Induction | 1999 |
Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gene Rearrangement; Genes, myc; Humans; Immunophenotyping; Karyotyping; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Translocation, Genetic; Vincristine | 1999 |
Hypophyseal non-Hodgkin's lymphoma presenting with diabetes insipidus: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Diabetes Insipidus; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Magnetic Resonance Spectroscopy; Male; Methotrexate; Middle Aged; Pituitary Neoplasms; Prednisone; Procarbazine; Tomography, X-Ray Computed; Vincristine | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Potassium; Sodium | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Diphenhydramine; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infusion Pumps; Infusions, Intravenous; Lorazepam; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Nausea; Patient Acceptance of Health Care; Prospective Studies; Safety; Self Care; Thiotepa; Vomiting | 1999 |
Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
Topics: Adult; Antigens, CD34; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Stem Cell Transplantation; Stem Cells | 1999 |
Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2000 |
A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Italy; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisone; Recurrence; Survival Rate; Vincristine | 2000 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Escherichia coli; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Prognosis; Respiratory Burst; Tetradecanoylphorbol Acetate | 2000 |
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelitis, Transverse; Neoplasm Invasiveness; Quality of Life; Radiation Injuries; Survival Analysis; Survival Rate; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infections; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Sweden; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
[Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Remission Induction; Vincristine | 1997 |
Pseudomembranous colitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Cyclophosphamide; Enterocolitis, Pseudomembranous; Etoposide; Humans; Intestinal Mucosa; Lymphoma, Non-Hodgkin; Male; Prednisone; Remission, Spontaneous | 2000 |
Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Prednimustine; Thrombocytopenia; Treatment Outcome | 2000 |
A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Survival Rate; Vincristine | 2000 |
Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4 Lymphocyte Count; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Recurrence; Survival Rate; Treatment Outcome; Vindesine | 2000 |
Interferon does not prolong progression-free survival after ProMACE-MOPP.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Interferon-alpha; Lymphoma, Non-Hodgkin; Mechlorethamine; Methotrexate; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Vincristine | 2000 |
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Middle Aged; Prognosis; Radiotherapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2000 |
Mobilization and transplantation of peripheral blood stem cells.
Topics: Antigens, CD34; Blood Transfusion; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Cytokines; Erythrocytes; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Paclitaxel; Platelet Transfusion; Regression Analysis; Retrospective Studies; Transplantation, Autologous | 1998 |
Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Phytogenic; Drug Therapy, Combination; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Transplantation, Autologous | 2000 |
[Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation, Autologous; Whole-Body Irradiation | 1998 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; California; Carmustine; Costs and Cost Analysis; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Graft Survival; Health Care Costs; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome; Whole-Body Irradiation | 2000 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Purging; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Cystitis; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infections; Leucovorin; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cytarabine; Epoetin Alfa; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Lymphoma, Non-Hodgkin; Melphalan; Platelet Transfusion; Recombinant Proteins; Treatment Outcome | 2000 |
Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Piperazines; Recurrence; Topoisomerase II Inhibitors | 2000 |
Should we always choose a nonparametric test when comparing two apparently nonnormal distributions?
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Data Interpretation, Statistical; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukocyte Count; Lymphoma, Non-Hodgkin; Methotrexate; Mitoguazone; Models, Statistical; Neutrophils; Numerical Analysis, Computer-Assisted; Sample Size; Software; Statistical Distributions; Statistics, Nonparametric; Stochastic Processes; Time Factors | 2001 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize.
Topics: Adult; Choriocarcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organophosphorus Compounds; Therapeutic Equivalency; Transplantation Conditioning; Whole-Body Irradiation | 2001 |
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD18 Antigens; Cell Movement; Chemotaxis, Leukocyte; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Filgrastim; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; Image Processing, Computer-Assisted; Lenograstim; Lymphoma, Non-Hodgkin; Methotrexate; Neutrophils; Prednisone; Protein Processing, Post-Translational; Recombinant Proteins; Vincristine | 2001 |
HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy, Needle; Cyclophosphamide; Doxorubicin; Etoposide; Flow Cytometry; HIV Infections; Humans; Immunohistochemistry; Immunophenotyping; Incidence; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prognosis; Thrombolytic Therapy; Venous Thrombosis; Vincristine | 2001 |
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Survival Rate | 2001 |
[High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Remission Induction; Treatment Outcome; Vincristine | 2001 |
Fatal hemolysis after high-dose etoposide: is benzyl alcohol to blame?
Topics: Acidosis; Africa; Alcohol Dehydrogenase; Benzyl Alcohol; Drug Combinations; Etoposide; Fatal Outcome; Hemolysis; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymorphism, Genetic; Respiratory Insufficiency; Seizures | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, Replacement, Hip; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Femur Head Necrosis; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Treatment Outcome; Vincristine | 2001 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Transplantation, Autologous | 2001 |
Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Recurrence; Regression Analysis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous | 2001 |
37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Adhesion Molecules; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunosuppressive Agents; Immunotoxins; Lectins; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Thalidomide; Vinblastine | 2001 |
High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cisplatin; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Humans; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2001 |
Immature teratoma of the ovary on fluid cytology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Biomarkers, Tumor; Bleomycin; Child; Cisplatin; Cytodiagnosis; Diagnosis, Differential; Etoposide; Female; Humans; Immunoenzyme Techniques; Lymphoma, Non-Hodgkin; Neuroblastoma; Ovarian Neoplasms; Rhabdomyosarcoma, Embryonal; Sarcoma, Ewing; Teratoma; Wilms Tumor | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Remission Induction; Tretinoin; Vincristine | 2002 |
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous | 2002 |
Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prognosis; Randomized Controlled Trials as Topic; Risk; Treatment Outcome | 2002 |
Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Infections; Ki-67 Antigen; Lymphocytes, Null; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Melanoma; Neoplasm Recurrence, Local; Neutrophils; Prednisone; Radiotherapy, Adjuvant; T-Lymphocytes; Vincristine | 2002 |
Non-Hodgkin's malignant lymphomata in adults: chemo-radiotherapy in stages III and IV.
Topics: Adult; Antineoplastic Agents; Azirines; Bleomycin; Cyclophosphamide; Daunorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Prednisone; Procarbazine; Teniposide; Triethylenemelamine; Vinblastine; Vincristine | 1975 |
Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Retrospective Studies; Vincristine | 1992 |
[Primary non-Hodgkin's lymphoma of paranasal sinuses. Review of the literature and a case report].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Ethmoid Sinus; Etoposide; Female; Frontal Sinus; Humans; Lymphoma, Non-Hodgkin; Maxillary Sinus Neoplasms; Methotrexate; Paranasal Sinus Neoplasms; Prednisone; Vincristine | 1992 |
Right ventricular outflow tract obstruction due to extrinsic compression by non-Hodgkin's lymphoma: importance of echocardiographic diagnosis and follow up.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Echocardiography; Etoposide; Humans; Lymphoma, Non-Hodgkin; Male; Prednisone; Pulmonary Valve Stenosis; Ventricular Function; Vincristine | 1992 |
A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone | 1992 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Whole-Body Irradiation | 1992 |
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Prednisolone | 1992 |
Constitutional translocation (8;13) in a patient with non-Hodgkin's lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Chromosome Banding; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Karyotyping; Lymphoma, Non-Hodgkin; Male; Prednisone; Translocation, Genetic; Vincristine | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Vincristine | 1992 |
Clinical oncology: case presentations from oncology centres. Intensive treatment of poor prognosis gastrointestinal lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Recombinant Proteins; Vincristine | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy; Texas; Vincristine | 1992 |
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Salvage Therapy; Vindesine | 1992 |
[Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Recurrence; Salvage Therapy; Survival Rate; Vindesine | 1992 |
[Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recurrence; Vincristine; Vindesine | 1992 |
Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy | 1992 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; Hydroxyurea; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Survival Rate; Thiotepa | 1992 |
Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vomiting | 1990 |
A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Staging; Prednisone; Prognosis; Remission Induction; Survival Rate | 1991 |
A clinical phase II study of ProMACE-CytaBOM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Vincristine | 1991 |
Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Vincristine | 1991 |
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Remission Induction; Survival Rate | 1991 |
Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Leucovorin; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Vincristine | 1991 |
Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Survival Analysis; Vincristine | 1991 |
[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoguazone; Neoplasm Staging; Prednisone; Procarbazine; Vincristine | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia; Liver; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
VP16 and TBI as conditioning regimen for allogeneic BMT in patients with high risk and relapsed ALL and NHL.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Reoperation; Risk Factors; Whole-Body Irradiation | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoguazone; Mitoxantrone; Remission Induction; Survival Rate | 1991 |
Establishment and characterization of a non-T, non-B cell lymphoma cell line with T cell receptor beta- and gamma-chain gene rearrangement and possessing MRK 20 monoclonal antibody-defined 85KD protein.
Topics: Aged; Drug Tolerance; Etoposide; Female; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Karyotyping; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Tumor Cells, Cultured | 1990 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Vincristine | 1991 |
Salvage therapy with PROMACE in relapsed non-Hodgkin malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prednisone | 1991 |
[Oral administration of etoposide therapy in refractory malignant lymphoma and adult T cell lymphoma].
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1991 |
Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Infusion Pumps; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation, Autologous | 1991 |
Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate | 1991 |
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Prospective Studies; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
Factors affecting the outcome of autologous bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Prognosis; Remission Induction; Survival Rate; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
[High-dose cyclophosphamide, thio-TEPA, etoposide with autologous bone marrow transplantation for refractory cancers].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Thiotepa | 1990 |
BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies | 1990 |
Chronic daily administration of oral etoposide.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal | 1990 |
ECAPP chemotherapy for lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Procarbazine; Vincristine | 1990 |
Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Whole-Body Irradiation | 1990 |
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Procarbazine; Remission Induction | 1990 |
High-dose etoposide and cisplatin in refractory or recurrent non-Hodgkin's lymphomas (NHL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction | 1990 |
Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Diabetes Mellitus; Dose-Response Relationship, Drug; Etoposide; Female; Glucose; Graft Rejection; Heart; Hodgkin Disease; Humans; Kidney; Liver; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies | 1990 |
Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Prednimustine; Prospective Studies; Survival Analysis | 1990 |
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Staging; Recurrence; Remission Induction | 1990 |
Erythema nodosum and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Erythema Nodosum; Etoposide; Female; Humans; Intestinal Obstruction; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Periarthritis; Prednisone | 1990 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoguazone; Recurrence; Remission Induction; Retrospective Studies | 1990 |
[Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoguazone; Prednimustine; Survival Rate | 1990 |
Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Procarbazine; Prognosis; Radiotherapy, High-Energy; Retrospective Studies; Vincristine | 1988 |
Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Vincristine | 1988 |
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Evaluation; Etoposide; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Vincristine | 1988 |
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Prednisolone; Remission Induction; Vindesine | 1989 |
Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Vincristine | 1989 |
High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Child; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1989 |
A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis | 1989 |
Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisolone; Remission Induction; Time Factors | 1989 |
EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prednisolone; Vincristine | 1989 |
Alternating six-drug combination chemotherapy induction for intermediate and high-grade non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisolone; Time Factors; Vincristine | 1989 |
Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Evaluation; Egypt; Etoposide; Female; Humans; Ifosfamide; Infant; Lymphoma, Non-Hodgkin; Male; Methotrexate; Remission Induction; Time Factors; Vincristine | 1989 |
Treatment strategies in relation to drug action.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Etoposide; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Podophyllotoxin; Teniposide | 1987 |
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Time Factors | 1989 |
Enhancement of etoposide-induced cytotoxicity by cyclosporin A.
Topics: Animals; Cells, Cultured; Cisplatin; Cyclosporins; Doxorubicin; Drug Interactions; Etoposide; Humans; Lethal Dose 50; Leukemia L1210; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Mice; Neoplasm Transplantation; Neoplasms, Germ Cell and Embryonal; Radiation, Ionizing | 1986 |
Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Hematologic Tests; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoguazone | 1988 |
[THP-COP, BHAC-VMP alternating chemotherapy in patients with non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Prednisone; Remission Induction; Vincristine | 1988 |
Methylprednisolone, etoposide, vindesine, and chlorambucil (PEEC) alone or alternating with CHOP as initial or salvage therapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Nausea; Prednisone; Prognosis; Remission Induction; Vincristine; Vindesine | 1988 |
High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Whole-Body Irradiation | 1987 |
[Clinical study on advanced non-Hodgkin's lymphoma with special reference to the results of chemotherapies with ACOP, ACOP-E and AclBEP regimen].
Topics: Aclarubicin; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes; Prednisolone; Sex Factors; Vincristine | 1987 |
[Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Leukemia; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1987 |
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung; Lymphoma, Non-Hodgkin; Prednisone; Radiography; Remission Induction; Respiratory Insufficiency | 1987 |
Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, vindesine, methotrexate with leucovorin rescue. Greek Lymphoma Research Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Etoposide; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Vindesine | 1987 |
High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Risk | 1986 |
Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone | 1987 |
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cytarabine; Drug Evaluation; Etoposide; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kidney Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged | 1987 |
Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Podophyllotoxin; Prednimustine; Prospective Studies; Teniposide | 1987 |
Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoguazone | 1986 |
Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male | 1987 |
[Chemotherapy for advanced diffuse non-Hodgkin's lymphoma with non-cross-resistant alternating AVCP/EMLP regimens].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone; Remission Induction; Vincristine | 1986 |
[Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone | 1987 |